 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 1of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015CLINICAL STUDY PROTOCOL V118_20 Version 1 .0
A Phase 3, Randomized, Double -Blind, Controlled, Multicenter, Clinical Study to 
Evaluate Safety and Immunogenicity of an MF59- Adjuvanted Quadrivalent Subunit 
Influenza Vaccine in Comparison with an MF59
-Adjuv anted Trivalent Subunit 
Influenza Vaccine and an MF59 -Adjuvanted Triva lent Subunit Influenza Vaccine 
Containing the Alternate B S train, in Adults Aged 65 Years and Above
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
Property of Seqirus Inc (hereafter referred to as Seqirus)
Confidential
May not be used, divulged, published or otherwise disclosed without written
consent of Seqirus.Doc ID: 83409929, Version: 1, Approval Date: 18May17

 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 2of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015TABLE OF CONTENTS
TABLE OF CONTENTS ................................................................................................ 2
PROTOCOL SYNOPSIS V1 18_20 VERSION 1 ............................................................. 6
LIST OF ABBREVIATION S........................................................................................ 27
1. BACKGROUND AND RATIO NALE ................................................................. 30
1.1 Background ..................................................................................................... 30
1.2 Rationale ......................................................................................................... 31
2. OBJECTIVES ...................................................................................................... 32
2.1 Primary Object ives.......................................................................................... 32
2.2 Secondary  Immunogenicit y Object ives............................................................ 32
2.3 Secondary  Safety Object ive:............................................................................ 32
2.4 Exploratory  Immunogenicit y Objectives .......................................................... 32
3. STUDY D ESIGN ................................................................................................. 33
3.1 Overview of Study  Design ............................................................................... 33
3.2 Study  Period.................................................................................................... 34
3.3 Blinding Procedures ......................................................................................... 35
3.4 Data Collect ion................................................................................................ 35
3.4.1 Data Collected from Subjects .................................................................... 35
3.4.2 Tool s Used for Data Collect ion................................................................. 36
3.5 Collect ion of Clinical Specimens ..................................................................... 37
3.6 Stopping/Pausing Guidel ines........................................................................... 38
3.7 Data Monitoring Committee ............................................................................ 38
3.8 Prem ature Wi thdrawal  from Study ................................................................... 38
3.9 End of Study .................................................................................................... 40
4. SELECTION OF STUDY P OPULATION ........................................................... 41
4.1 Inclusio n Cri teria............................................................................................. 41
4.2 Exclusio n Cri teria............................................................................................ 41
4.3 Criteria for Del ay of Vaccinat ion..................................................................... 42Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 3of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 20155. STUDY PROCEDURES ...................................................................................... 43
5.1 Prevaccinat ion Clinic Visit(s) .......................................................................... 43
5.1.1 Inform ed Consent ..................................................................................... 43
5.1.2Screening .................................................................................................. 44
5.1.3 Enrollment ................................................................................................ 47
5.1.4 Randomization .......................................................................................... 47
5.2 Vaccinat ion Clinic Visit(s) ............................................................................... 47
5.2.1 Postvaccinat ion Procedures ....................................................................... 48
5.2.2 Postvaccinat ion Reminder Call ................................................................. 49
5.3 Postvaccinat ion Clinic Visit and Safet y Calls ................................................... 49
5.3.1 Follow-up Clinic Visit .............................................................................. 50
5.3.2 Saf ety Follow-up Phone Calls ................................................................... 51
5.4 Unscheduled Visits .......................................................................................... 52
5.4.1 Subjects Meeting Influenza -Like-Illness Cri teria......................................... 52
5.5 Study  Terminat ion Phone Call ......................................................................... 52
5.5.1 Early Terminat ion Visit ............................................................................. 53
6. T REATMENT OF SUBJECTS ............................................................................ 54
6.1 Study  Vaccines ................................................................................................ 54
6.2 Non-Study  Vaccines ........................................................................................ 59
6.3 Vaccine Preparation and Administration .......................................................... 59
6.4 Vaccine Administration Error or Overdose of Vaccine ..................................... 59
6.5 Prior and C onco mitant Medicat ions and Vaccines ............................................ 60
6.6 Vaccine Supply, Labeling, Storage and Tracking ............................................. 62
7. ASSESSMENTS .................................................................................................. 64
7.1 Safety Assessment ........................................................................................... 64
7.1.1 Solicited Adverse Events .......................................................................... 64
7.1.2 Unsolicited Adve rse Events ...................................................................... 66
7.1.3 Evaluat ion of Adverse Events ................................................................... 66Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 4of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 20157.1.4 Serious Adverse Events ............................................................................. 68
7.1.5 Adverse Events of Special Interest ............................................................ 69
7.1.6 Methods for Recording and Reporting Adverse Events and Serious Adverse 
Events ....................................................................................................... 69
7.1.7 Pregnancies ............................................................................................... 70
7.1.8 Safety Laboratory  Measurements .............................................................. 70
7.2 Efficacy Assessment ........................................................................................ 71
7.3 Immunogenicit y Assessment ............................................................................ 71
8. STATISTICAL CONSIDER ATIONS .................................................................. 72
8.1 Endpoints ......................................................................................................... 72
8.1.1     Primary  Endpoints ................................................................................... 72
8.1.2 Secondary  Imm unogenici ty Endpo ints..................................................... 73
8.1.3 Secondary  Safety Endpo ints..................................................................... 73
8.1.4 Exploratory  Immunogenicit y Endpoints .................................................... 74
8.2 Success Criteria ............................................................................................... 74
8.2.1 Success Criteria for Co -Primary Endpo ints............................................... 74
8.2.2       Success Criteria for Secondary  Objectives ........................................... 75
8.3 Descript ion of Analysis Sets ............................................................................ 75
8.3.1 All Enrolled Set ........................................................................................ 75
8.3.2 Full Analysis Set .......................................................................................... 76
8.3.3 Safety Set.................................................................................................. 76
8.3.4 Evaluable Set –Immunogenicit y Analysis ................................................ 76
8.3.5 Per-Protocol Set ........................................................................................ 76
8.3.6 Subgroups ................................................................................................. 77
8.3.7 Protocol  Deviat ions................................................................................... 77
8.4 Statistical Analysis Plan ................................................................................... 78
8.4.1 Analysis of Demographic and Baseline Characteristics ............................. 78
8.4.2 Analysis of Pr imary Objective(s) .............................................................. 79
8.4.3 Analysis of Secondary  Object ive(s)........................................................... 83Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 5of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 20158.4.4 Secondary  Safety  Objective ......................................................................... 85
8.4.5 Analysis o f Exploratory  Object ives.............................................................. 87
8.5 Sample Si ze and Power Considerations ............................................................ 88
8.6 Interim Analysis .............................................................................................. 91
9. SOURCE DOCUMENTATION , STUDY MONITORING A ND AUDITING .....92
9.1 Source Documentation ..................................................................................... 92
9.2 Study  Moni toring, Audi ting and Source Data Verificat ion............................... 93
10. DAT A MANAGEMENT ..................................................................................... 94
10.1 Data Entry  and Management ............................................................................ 94
10.2 Data Cl arificat ion............................................................................................ 94
10.3 Data Protection ................................................................................................ 94
11. RECORD RETENTION ....................................................................................... 95
12. USE OF INFORMATION A ND PUBLICATION ................................................ 96
13. ETHICAL CONSIDERATIO NS.......................................................................... 97
13.1 Regulatory  and Ethi cal Com pliance ................................................................. 97
13.2 Inform ed Consent Procedures .......................................................................... 97
13.3 Responsibilit ies o f the Invest igator and IRB/EC ............................................... 97
13.4 Protocol  Amendments ...................................................................................... 99
14. REFERENCE LIST ............................................................................................ 100
APPENDIX 1: EXAMPLES OF PRE -EXISTING MEDICAL CON DITIONS FOR 
CALCULATION OF RISK SCORE .................................................................. 103Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 6of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015PROTOCOL SYNOPSIS V118_20 VERSION 1
Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
Title of Study: A Phase 3, Rando mized, Double -Blind, Controlled, Mult icenter, 
Clinical Study  to Eval uate Safety  and Immunogenici ty of an MF59 -Adjuvanted 
Quadrivale nt Subunit Influenza Vaccine in Co mparison with an MF59 -Adjuvanted 
Trivalent Subunit Influenza Vaccine and an MF59 -Adjuvanted Trivalent Subunit 
Influenza Vaccine Containing the Alternate B strain, in Adult s Aged 65 Years and 
Above
Study Period: The total study peri od for a 
subject will be approximately  6months 
following a single vaccinat ion.Clinical Phase: 3
Background and Rationale: Influenza is an infectious disease caused by the influenza 
virus, an orthomyxo virus with two clinically relevant ty pes (t ypes A and B). The disease 
is characterized by  the abrupt onset of respiratory  and systemic symptoms, such as 
fever, myalgia, headache, severe malaise, nonproductive cough, sore throat, and rhinit is, 
and occurs in epidemics throughout the northern and sout hern hemisphere winter 
months in temperate climates. During influenza epidemics, there is increased mortalit y 
among ol der adul ts (age >65 years) and people with chronic diseases, as well as an 
increase in morbidit y and hospi talizati on because of influenza -associ ated com plicat ions.
The abilit y of vaccinat ion to prevent influenza in older adults appears to be lower 
compared wi th younger adul ts, possibly because of a less robust immune response after 
influenza vaccinat ion. One way to increase immunogenicit y of influenza vaccines is 
through the use of adjuvants, such as the squalene and water emulsio n adjuvant, MF59.  
Fluad, Seqirus’ trivalent seasonal influenza vaccine adjuvanted with MF59, has been 
licensed for use in Europe since 1997 and in the US since 201 5. It has been shown to 
generate significant ly higher geometric mean hemagglut ination inhibit ion (HI) ti ters and 
rates of seroconversio n than a non -adjuvanted trivalent influenza vaccine comparator in Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 7of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
elderly  subjects. Tri valent influenza vaccines contain just one B strain antigen. 
Influenza ty pe B vi ruses, however, have separated into two dist inct genet ic lineages 
since 1985, Yamagata and Victoria. B strains fro m either lineage may  circulate and 
cause infect ion, and mismatch may  occur between ci rculat ing B strains and the strain 
contained in a trivalent vaccine. On average, influenza B strain accounts for 
approximately  25% of  posi tive specimens in the US. Mismatches between the B strain 
in a trivalent vaccine and the circulat ing strain occur in approximate ly half o finfluenza 
seasons. To overcome this, several quadrivalent inactivated influenza vaccines are now 
licensed in the US, containing representative vaccine strains for both B -strain lineages, 
as well as the H1N1 and H3N2 A subty pes. 
The invest igatio nal product (aQIV) i s an MF59- adjuvanted subunit inactivated 
quadrivalent influenza virus vaccine. A 0.5 mL dose is formulated to contain 15 mcg 
hemagglut inin (HA) of each included influenza virus strain, including representative 
strains of both B lineages . The aQIV form ulation is consistent with the current ly 
licensed Fluad trivalent influenza virus vaccine (aTIV), except that it contains an 
additional B influenza strain so that the total HA concentrati on is 60 m cg HA/0.5 mL 
dose, from  four strains.
The ai m of this study  is to dem onstrate that inclusion of an addit ional B vaccine strain 
elicits an immune response to the second B virus and does not adversely  impact the 
patient’s immunogenicit y response against strains previously included in trivalent 
formulations. Addi tionally, the aim is to demonstrate and confirm an acceptable safet y 
and tol erabilit y profile for the quadrivalent influenza vaccine formulat ion in the elderly 
popul ation.
Data from this study  will be used to support the licensure of aQIV for th e prevent ion of 
seasonal influenza in adults ≥ 65 y ears of age.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 8of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
Study Objectives:
Co-Primary Immunogenicity Objectives:
1.To dem onstrate that vaccinat ion with aQIV elicit s an immune response that is 
not inferior to that of an aTIV con taining the same virus s trains as the US 
licensed adjuvanted influenza vaccine (Fluad, aTIV -1), and an aTIV 
containing the alternate B strain (aTIV -2) among adults ≥65 y ears of age.
2.To assess the immunogenicit y of aQIV in adults ≥65 years of age, based on 
the CBER (Center for Bio logics Evaluat ion and Research) recommendat ions.
Secondary Immunogenicity Objectives:
The secondary  objectives of the study  are to assess the fo llowing, am ong adul ts aged ≥ 
65 years: 
1.To characterize the immunogenicit y of aQIV, the aTIV -1 containing the sa me 
virus strains as the US licensed adjuvanted trivalent influenza vaccine, and the 
aTIV -2 containing the alternate B strain ,by he maggl utination inhibit ion (HI) . 
2.To dem onstrate the immunological superiorit y of aQIV com pared to aTIV -1 and 
aTIV -2 for the B strain that is not included in each TIV vaccine separately;
Secondary Safety Objective:
1.To assess safet y and tol erabili ty of aQIV, aTIV -1, and aTIV -2 among adults >
65 years of age.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 9of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
Exploratory Immunoge nicit yObjective s:
1.To expl ore the associ ation betwee n HI immune response after administration 
of aQIV or the aTIV -1, containing the same virus strains as the US -licensed 
adjuvanted trivalent influenza vaccine, and the aTIV -2 containing the 
alternate B strain by  baseline characteristics.
2. C haracteri zation of the immunogenicit y of aQIV using other immuno logical 
assays (e .g., virus neutralization [MN] or anti -neuraminidase ant ibody  assays 
may be performed).
Both exploratory object ives may be perform
ed using ei ther hom ologous or heterol ogous 
strains, or both.
Study Design: This phase 3 study  is a randomized, double -blinded, comparator 
controlled, parallel -group, m ulticenter study  of aQIV versus the US -licensed 2017 -2018 
adjuvanted trivalent influenza vaccine (aTIV -1, Fluad ),and versus an adjuvanted 
trivalent inf luenza vaccine (aTIV -2), containing the alternate B strain. All study  vaccine 
administration will be a single dose, and consistent with the current license for aTIV
-1.
The study  will be conducted in approximately 1778 male and female adults aged 65 
years a nd older who are healthy or have co -morbidities which increase their risk of 
complicat ions from influenza infect ion. Subjects will be rando mized to one of the three 
treatm ent groups in a 2:1:1 ratio. An Interactive Response Techno logy (IRT) sy stem  
will be used f or subj ect randomizat ion.
Subjects will provide sero logical specimens during the two m andatory  clinic visi ts 
before and after vaccinat ion on Day 1 and Day 22for measurem ent of  immune 
responses in routine influenza assays. Each s ubject will complete a Diary Card for 
solicited local and systemic adverse events for 7 days after vaccinat ion. Safet y 
inform ation will also be co llected forall unso licited AEs for 21 day s following 
vaccination; and for the full duration of study  partici pation forserious AEs (SAEs), AEs Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 10of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
leading to withdrawal fro m the study , new onset of chronic diseases (NOCDs), AEs of 
special interest (AESIs), and concomitant medicat ions associated with these events. 
Three scripted safet y telephone calls will facilitate the collect ion of the se safet y data 
during the study  period, and one reminder phone call will occur during the first few 
days after vaccinat ion to remind the subject on the complet ion of the Diary Card.
An unscheduled study  visit may be perform ed at any  time during the study to further 
evaluate safety  informat ion described on the telephone .
Any subject who manifests signs of an influenza -like illness during the Treatm ent
Period (Day s 1-22) will be evaluated by real time reverse transcript ion polymerase 
chain react ion (RT -PCR) t esting o f a nasopharyngeal (NP) specimen for influenza. 
Subjects with onset of ILI and RT -PCR -confirmed influenza during the Treatm ent
Period (Day s 1-22) will be removed from the Per Protocol Set (PPS) in the 
immunogenicit y analyses. ILI will also be recor ded as an adverse event.
Number of Subjects planned: Approximately 1778 subjects will be enro lled into this 
study . In order to have 800 evaluable subjects in the aQIV group and 400 evaluable 
subjects in each aTIV group, and considering 10% for drop -outs, approximately 1778 
are needed to be enrolled into this study . The subjects will be distributed among the 
vaccine groups in a ratio of 2:1:1 (aQIV:aTIV -1:aTIV -2).
Study Population and Subject Characteristics : This study  will enroll males and 
females ≥65 ye ars ol d who are healthy or have co -morbidities. The list of inclusio n and 
exclusio n criteria i s included in protocol Section 4, Select ion of Study  Popul ation.
Study Procedures: 
Written inform ed consent m ust be obtained prior to any  study -related procedures. The 
inform ed consent process may be conducted up to 10 day s before day  of vaccinat ion 
(Day  1). Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 11of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
Treatment Period: Day 1 through Day 22
After informed consent is signed by the subject or legal representative , on and p rior to 
vaccination on Day  1, eval uations will be performed and will include relevant medical 
history , physical  examinat ion, and vital signs. A blood sample will be co llected fro m all 
eligible subjects f or influenza- specific sero logy testing . All eligibili ty assessments need 
to be completed prior to blood sample collection. Subjects will be assessed for risk of 
complicat ions from influenza using the standardized scoring system described by Hak 
(2004).
All eligible subjects will then r eceive a single dose of 0.5 mL of study  vaccine to which 
they were assigned, administered intramuscularly  in the del toid muscle, preferably of 
the non -dominant arm.
After vaccination, all subjects will remain under medical supervisio n at the study  site 
forat least 30 minutes to be monitored and evaluated for local and systemic adverse 
event s (AEs).
Subjects will receive a thermo meter, a ruler ,and a Diary Card, along with instructions 
to ensure proper complet ion;they will note any  occurre nce of so licited local and
systemic AEs, and record their oral temperatures , preferably in the evening, for events 
occurring on Day  1 through Day  7. The Di ary Card will only  be used to coll ect soli cited 
adverse events and temperature measurements .
A reminder telephone call will be made on Day  3 (window, Day  2 to Day  4) to remind 
the subject to complete the Diary  Card and to return the Diary  Card at the Day 22 clinic 
visit, when the D iary Card data and informat ion on unso licited AEs will be verbally  
collected and reviewed.
Ascripted safet y telephone call will be made by sit e staff to subjects on Day  15 Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 12of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
(window: Day  12 to day  18) to collect any  unsolicited AEs and any use of concomitant 
medicat ions: these will be captured in source documents and the electroni c Case Report 
Form (CRF ).Subjects with symptoms o f ILI will be reminded to return to the study  site 
for nasopharyngeal swab testing. 
Subjects will return to the clinic on Day  22 (window, Day  19to Day  25) f or a m edical 
examinat ion, and to provide a serum sample for serol ogic testi ng. During this visit the
Diary Card will be co llected and all unso licited AEs and concomitant medicat ion use 
(occurring after vaccinat ion between Day 1 and Day 22) will be documented in the 
subject’s source records and captured in the CRF .
Any s ubject who m anifests si gns of an influenza -like illness (ILI, defined as at least one 
of the fo llowing respi ratory  symptom s[new onset or exacerbat ion of pre -exist ing 
condi tion]: sore throat, cough, sputum production, wheezing, or difficult y breathing; 
concurrent ly wit h at l east one of the fo llowing systemic symptoms: temperature of 
>37.2°C/ 99°F, chills, tiredness, headache, or myalgia) during the Treatment Period 
(Day s 1
-22) will be asked to come in to the site within 3 days o f the onset of the ILI in 
order to have a nasopharyngeal (NP) swab collected for evaluat ion of the presence of 
influenza virus using RT -PCR. However ,samples will  be accepted if collected up to 6 
days fo llowing the day  of ILI onset. Swabs will be sent to a qualified central laboratory
as specified in the Clinical Invest igator Laboratory Manual.
Follow -up Period: Day 23 through Day 181
A scripted safet y telephone call will be made on Day  91 (window: Day  84 to Day  98) to 
collect only those unsolicit ed AEs that are: serious AEs (SAEs), AE s leading to study  
withdrawal , new onset of chronic diseases (NOCDs), adverse events of special interest 
(AESIs); and conco mitant medicat ions associated with these events. 
A scripted safet y telephone call will be made on Day  181 (window: Day  167 to Day  Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 13of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
195) for assessment of SAEs, AEs leading to study withdrawal, NOCDs, and AESIs; 
and conco mitant m edicati ons associated wi th these events.
An unscheduled study  visit may be perform ed as necessary  for further evaluati on of  
safet y informat ion that i s described on the tel ephone that i s to be investigated further at 
any time during the study .
If a subject withdraws fro m the study , they  will be asked to undergo a final assessment 
for safet y.
Study Vaccines: Regardless of the type of a vaccine assigned in the trial , subjects will 
receive a 0.5 mL dose. All three influenza vaccines are made similarly, wit h the 
exception of the influenza strains included.
Quadrivalent Influenza Test Vaccine ( aQIV, investigational vaccine )
An adjuvanted inactivated subunit quadrivalent influenza vaccine, administered as one 
0.5 m L intramuscular dose into the deltoid muscle. The vaccine is presented in a 
prefilled needleless syringe. Each 0.5 mL dose contains 15 mcg hemagglut inin (HA) 
from each of the fo llowing four influenza strains (recommended by  the World Heal th 
Organizat ion for the 2017 -2018 Northern Hemisphere influenza season for quadrivalent 
vaccines:
15 mcg per 0.5 mL dose A/Michigan/45/2015 (H1N1)pdm09 -like virus; 
15 mcg per 0.5 mL dose A/Hong Kong/4801/2014 (H3N2) -like virus; 
15 mcg per 0.5 mL dose B/Bri sbane/60/2008- like virus (B/Victoria lineage):
15 mcg per 0.5 mL dose B/Phuket/3073/2013 -like virus (B/Yamagata lineage).
Licensed Trivalent Influenza Co mparator Vaccine 1 (aTIV -1, Trade name: Fluad)
An adjuvanted inactivated s ubunit trivalent influenza vaccine, administered as one 0.5 
mL intramuscular dose into the deltoid muscle. The vaccine is presented in a prefilled Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 14of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
needleless syringe.
Each 0.5 mL dose contains 15 mcg HA from each of the fo llowing three influenza 
strains (t wo influenza A strains and one B strain recommended for a trivalent influenza 
vaccine by the World Heal th Organizat ion for the 2017 -2018 Northern Hemisphere 
influenza season :
15 mcg per 0.5 mL dose A/Michigan/45/2015 (H1N1)pdm09 -like virus; 
15 mcg per 0.5 mL dose A/Hong Kong/4801/2014 (H3N2) -like virus; 
15 mcg per 0.5 mL dose B/Bri sbane/60/2008- like virus (B/Victoria lineage).
Trivalent Influenza Co mparator Vaccine 2, with alternate B strain (aTIV -2, 
investigational vaccine)
An adjuvanted inactivated subu nit trivalent influenza vaccine, administered as one 0.5 
mL intramuscular dose into the deltoid muscle. The vaccine is presented in a prefilled 
needleless syringe. Each 0.5 mL dose contains 15 mcg HA from each of the fo llowing 
three influenza strains ( two influenza A strains recommended for a trivalent influenza 
vaccine by the World Heal th Organizat ion for the 2017 -2018 Northern Hemisphere 
influenza season. and the alternate B strain to that recommended for TIV :
15 mcg per 0.5 mL dose A/Michigan/45/2015 (H1N 1)pdm 09-like virus; 
15 mcg per 0.5 mL dose A/Hong Kong/4801/2014 (H3N2) -like virus; 
15 mcg per 0.5 mL dose B/Phuket/3073/2013
-like virus (B/Yamagata lineage).
Co-Primary Immunogenicity Endpoint(s): 
The immunogenicit y of study  vaccines will be assessed 21 days (ie, on Day  22) after 
vaccine administration by measuring the hemagglutinat ion inhibit ion (HI) antibody  Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 15of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
titers to the four virus strains included in the vaccines.
The noninferiorit y of aQIV com pared to aTIV -1, and to aTIV -2 will be assessed for th e 
eight co -primary endpo ints of HI geom etric mean titer (GMT) and seroconversio n rate 
(SCR) for each virus strain included in the vaccines as fo llows:
The GMT rati o* for the A/H1N1 strain;
The GMT rati o for the A/H3N2 strain;
The GMT rati o for the B strain (Yamagata lineage);
The GMT rati o for the B strain (Victoria lineage);
The difference between the SCR**for the A/H1N1 strain;
The difference between the SCR for the A/H3N2 strain;
The difference between the SCR for the B strain (Yamagata lineage);
The dif ference between the SCR for the B strain (Victoria lineage).
Immunogenicit y resul ts obtained from  aTIV -1 and aTIV -2 for both A/H1N1 and 
A/H3N2 strains will be pooled for comparison wit h aQIV.
*The GMT ratio is defined as the geometric mean of the post - vaccination (Day 22) HI titer for aTIV -1 (or 
aTIV -2) over the geometric mean of postvaccination (Day 22) HI titer for aQIV.
**The SCR is defined as the percentage of subjects with either a prevaccination HI titer < 1:10 and a 
post-vaccination HI titer ≥ 1: 40 or a prevaccination HI titer ≥ 1:10 and a ≥ 4 -fold increase in 
postvaccination HI titer.
The second co -primary immunogenicit y objective for aQIV will be assessed 21 day s 
after vaccine administration by applying CBER criteria for the elderly populat ion for 
each of the 4 strains included in aQIV:
The percent of subjects achieving seroconversio n for HI antibodyDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 16of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
The percent of subjects achieving an HI antibody  titer ≥ 1:40
The study  is considered successful  if the all co-primary endpo ints are achieved.
Co-prima ry Immunogenicity Objective 1 -Criteria to demonstrate noninferiority:
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance for 
Industry  Clinical  Data Needed to Support Licensure of Seasonal Inact ivated Influenza 
Vaccines 2007), aQIV will be considered to be noninferior to aTIV-1 , containing the 
same virus strains as the US licensed adjuvanted trivalent influenza vaccine, and aTIV -
2, containing the alternate B strain if, for each of the four strains, the fo llowing 
statist ical criteria are m et:
The upper bound of the two -sided 95% confidence interval (CI) for the ratio of 
the GMTs (GM Tr) does not exceed 1.5. The GMTrwill be calculated as GMT 
aTIV/GMT aQIV; and
The upper bound of the two -sided 95% CI for the difference between t he SCRs 
does not exceed 10%. The difference in SCRs will be calculated as SCR aTIV–
SCR aQIV
C
o-primary Immunogenicity Objective 2 –CBER C riteria:
The endpo ints for percent of subjects vaccinated with aQIV achieving seroconversio n 
and HI ti ter ≥ 1:40 at Day 22 will be assessed against the criteria described in CBER 
Guidance Clinical Data Needed to Support the Licensure of Seasonal Inact ivated 
Influenza Vaccines ( FDA, 2007):
The l ower bound of the two
-sided 95% confidence interva lfor the percentage of 
subjects achieving seroconversio n for HI antibody  shoul d meet or exceed 30%.
The l ower bound of the two- sided 95% confidence interval for the Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 17of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
percentage of subjects achieving an HI a ntibody  titer ≥ 1:4 0should meet or 
exceed 60%.
The stati stical evaluat ion consists of the observed proportion together with the 
correspondi ng two -sided 95% CI interval per strain. 
No adj ustment for type I error for m ultiplicity will be made. The study  issuccessful if 
the co-primary immunogenicit yobjectives are achieved.
Secondary Immunogenicity Endpoint(s): 
The m easures of immunogenicit y of aQIV, aTIV -1 and aTIV -2 used for 
Secondary  object ive 1 as determined by the HI assay against ho molo gous 
strains a t Day  1 and 22 (unless indicated otherwise), include the following:
oGMT: Geom etric mean of HI ti ters on Day  1 and Day  22; 
oGeom etric mean rati o (GMR)*: The geom etric m ean of the fo ld increase of 
postvaccinat ion HI titer over the pre vaccinat ion HI titer (Da y 22/Day 1);
oThe percentage of subjects with a titer ≥ 1:40 at Day 1 and Day 22 ;
oSCR: the percentage of subjects with either a prevaccination HI titer < 1:10 
and a postvaccinat ion HI ti ter ≥ 1:40 or a prevaccinat ion titer ≥ 1:10 and a 
≥ 4-fold increase in postvaccinat ion titer on Day  22.
For secondary  objective 2 the immunologic superiority HI ant ibody  responses of 
the alternate B strain (the influenza B strain included in the aQIV but not in the 
aTIV formulat ion) in aQIV will be assessed separately , by theendpo ints of the 
ratio of HI GMT and the difference of SCR for each B virus strain 21 days after 
the last vaccinat ion in subjects . Superiorit y of aQIV over aTIV -1 and aTIV -2 
for antibody  response to the alternate B strain will be assessed using the GMT 
ratio (aTIV/aQIV) and difference in SCR (aTIV –aQIV) at Day  22. Point 
estimates and 95% confidence limits will be obtained as described for the 
primary endpoint. Superi ority will be declared if the upper limit of the two -Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 18of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
sided 95% CI for the difference in S CR (aTIV –aQIV) is < 0 and the upper 
limit of the two sided 95% CI for the GMT ratio (aTIV/aQIV) is < 1 for both B 
strains
Secondary S afety Endpoints:
Safety and tol erabilit y will  be assessed by  the f requency and severit y of:
Solicited local and systemic adverse events (AEs) for 7 days fo llowing 
vaccinati on (Day  1 through Day  7)
All unso licited AEs for 21 days fo llowing vac cinati on (Day  1 through Day  
22)
Serious AEs (SAEs), AEs leading to withdrawal from the study , new onset of 
chronic diseases (NOCDs), A Es of  special  interest (AESIs), and concomitant 
medicat ions associated with these events as collected fro m Day 1 through 
Day 181.
Exploratory Endpoint(s): 
Exploratory  immunogenicit y endpo ints include:
oGMTs: Geometric mean HI titers (GMTs) at Day  1 and Day 22
oSCRs: Percentage of subjects with either a prevaccinat ion HI titer < 1:10 
and a postvaccinat ion HI ti ter ≥ 1:40, or a prevaccinat ion titer ≥ 1:10 and a 
≥ 4-fold increase in postvaccinat ion titer at Day  22
In case of any addit ional optional immunogenici ty analyses, such as MN, or 
assessments using heterologous influenza strains, the immune response will 
be characterized in a similar manner as described in the secondary Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 19of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
immunogenicit y endpo ints sect ion above.
Further details regarding the endpo ints and an alyses of these assays will be described in 
the Statistical Analysis Plan (SAP) prior to unblinding.
Statistical Analyses:
Sample Size Estimation:
aQIV will be tested against aTIV comparators. The treatment randomizat ion rati o is 
2:1:1 (aQIV: aTIV -1: aTI V-2). This study is powered to achieve 80% power to 
demonstrate noninferiori ty over 8 co -primary endpoints, seroconversio n rates for 4 
strains, GMT for 4 strains using a one- sided alpha of 0.025 for each comparison. No 
adjustm ent for multiple endpoints wil l be made.
For com parisons of SCR a noninferiorit y margin of 10% (aTIV –aQIV) will be 
employed.It is assumed that the SCRs for A/ H1N1, A/ H3N2 and B strains for TIV are 
73%, 73% and 40% respectively. These estimates are based onthe estimated SCR rates 
of histori cal data, nam ely study  protocol  V70_27 . It has been assumed that there is no 
difference in terms of SCR between aQIV and aTIV for all strains. For comparison of 
GMT ratio a noninferiorit y margin of 1.5 (aTIV/aQIV) will be emplo yed. It is assumed 
that there is no difference between aQIV and aTIV ( i.e.a rati o of 1) and that the 
standard deviat ion of log (titer) is 1.2.
Under these assumptions, N evaluable = 800 in the aQIV group and 400 in each aTIV 
group provi ding 800 and 800 subjects receiving aQ IV and aTIV respectively  for 
comparisons of A strains, and 800 and 400 subjects receiving aQIV and aTIV 
respectively  for com parisons o f B strains. This provides a total N evaluable = 1600. 
These numbers provide 99.45% power to detect differences in SCR for each A strain 
and 91.29 % power for each B strain, providing overall 82.42% power for the 4 SCR Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 20of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
tests.
For GMT ratio tests each A strain test will have 100% power and each B strain test will 
have 99.98% power, providing 99.96% power for the 4 GMT ratio te sts and 
consequent ly 82.39% power for the 8 co -primary endpo ints.  Overall 1600 evaluable 
subjects will be required. Allowing for a 10% drop -out N=1778 subjects will be 
recrui ted (Sam ple size calculat ions were performed using PASS v12).
The immunogenicit y was powered to m eet the cri teria prespecified in the CBER 
guidance for acceptable immunogenicit y: namely, 
the lower bound of the two -sided 95% confidence interval for the percent of 
subjects achieving seroconversio n shoul d exceed 30%, and 
the lower bound of the two -sided 95% confidence interval for the percent of 
subject achieving HI ant ibody titer ≥ 40 should exceed 60%
With a sample size of N=800 (evaluable) subjects for the aQIV group if the population 
SCR for A/ H1N1, A/ H3N2 and B strains for TIV is 73%, 73% and 40% respectively 
then the probabilit y of observing a seroconversio n rate that is significant ly greater than 
30% i s approximately  100% (f or the A/H1N1), 100% for A/H3N2 and 100% (for the B -
strains).
With a sample size of N=800 (evaluable) subje cts for the aQIV group ,if the populat ion
titer >1:40 rates for A/ H1N1, A/ H3N2 and B strains for TIV are91%, 99% and 64.6% 
respectively  (as observed in V70_27) then the probabilit y of observing a SP rate that is 
significant ly greater than 60% is approx imately 100% (for the A/H1N1), 100% for 
A/H3N2 and 76.47% (for the B- strains).Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 21of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
Analysis Populations:
The All Enro lled Set will co mprise all subjects providing informed consent who are 
assigned a subject ID, and provide demographic and/or screening informa tion.
The Full Analysis Set (FAS) will co mprise all subjects randomized and receive a study  
vaccine. 
The Safet y Set will co mprise all subjects in the FAS who received at least one dose of 
study  vaccine and have provided fo llow-up safet y data. Thi s popul ation will  be used to 
summarize and list all safet y information.
The Evaluable Populat ion will co mprise all subjects in the FAS who:
receive vaccine on Day 1;
provi ded pre -and postvaccinat ion blood samples;
did not experi ence laboratory -confi rmed influenza illness; between Day  1 and 
Day 22; and
did not receive any  contraindicated m edicat ion during the study  that is m edically 
assessed to potentially impact immunogenicit y resul ts.
The Per Protocol Set will co mprise all subjects in the evaluable populat ion who do not 
have any protocol deviat ions felt to potenti ally impact immunogenicit y resul ts.
The Per Protocol Set will be the primary  popul ation of interest for the 
primary /secondary immunogenicit y analysis and a supporting analysis will be 
perform ed using the E valuable Populat ion.Duplicate tables o f primary  and secondary 
immunogenicit y analyses m ay also be produced based on the Evaluable population if 
there is >1% difference in the total number of subjects between the Per -Protocol Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 22of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
Popul ation and the Evaluable P opulati on.
Evaluation of Co -Primary Immunogenicity E ndpoints:
Noninferiority
To determine the GMT ratio (adjusted analysis) a general linear model (GLM) will be 
fitted on l og transform ed (base 10 ) post -vaccination HI titer as the outcome variable and 
termsfor covari ates: vaccine treatment, pre -vaccination HI titer, age stratum (≥65-74, 
≥75-84, and ≥85y ears), gender , vaccinat ion history, age -by-vaccine interact ion and 
study  site.Potential  covariate interacti on effects will also be examined in the fit of the 
GLM. From the model, an adjusted difference in least square means (on th e log scale) will 
be produced with 95% confidence limits. The estimated difference and the confidence limits 
will be back transformed to obtain an adjusted GMT ratio with 95% confidence limits. Each 
of the four strains will be analyzed separately. The adju sted GMT ratio will be the result for 
which the non -inferiority assessment of the HI GMT co -primary endpoint will be based on. 
The stati stical models might be reduced in case they  fail to converge. Further details 
will be provided in the Statist ical Analy sis Plan
The complete set of covariates that will be used in the model to calculate the adjusted 
GMT ratio will include treatment group (3 treatments), age sub -group, sex (male or 
female), influenza vaccinat ion received prior year (Y or N), prevaccination mean GMT 
titer (val ue) and invest igator site (site ident ifier)
The GLM specificat ion is: Adjusted Analysis GMT Model: Log -transformed Post -
vaccination HI Titer = Vaccine + Age Strata + Gender + Vaccinat ion History  [y/n] + 
Log-transform ed Prevaccinat ion HI Titer + Si te + Age Strata*Vaccine.
The m easure of the unadjusted GMT ratio based on postvaccinat ion GMTs only  will Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 23of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
also be presented.
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance 
for Industry Clinical Data Needed to Su pport Licensure of Seasonal Inactivated 
Influenza Vaccines 2007) .  aQIV will be considered to be non -inferior to aTIV if, for 
each of the four strains, the fo llowing stati stical criteria are met: 
The upper bound of the two -sided 95% Confidence Interval (C I) for the ratio of the 
GMTs does not exceed 1.5. The GMT ratio will be calculated by 
GMT aTIV/GMT aQIV. 
The upper bound of the two -sided 95% CI for the difference between the SCRs does 
not exceed 10%. The difference in SCR will be calculated by SCR aTIV–SCR aQIV.
CBER Cri teria:
To achieve the co- primary CBER criteria: 
The l ower bound of the two- sided 95% confidence interval for the percentage of 
subjects achieving seroconversio n for HI antibody  shoul d meet or exceed 30%.
The l ower bound of the two- sided 95 % confidence interval for the percentage of 
subjects achieving an HI antibody  titer ≥ 40shoul d meet or exceed 60%.
To m eet the CBER cri teria, both endpoints should be met for each strain included in 
aQIV arm.
The stati stical evaluat ion consists of the observed proportion together with the 
correspondi ng two -sided exact 95% confidence interval per strain. No adjust ment for 
type I error for m ultiplicity is made.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 24of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 2015Name of Sponsor:
Seqirus Inc.Protocol 
number:
V118_20Generic name of study vaccine(s):
MF59 -adjuvanted Quadrivalent Subunit Inact ivated 
Egg-derived Influenza Vaccine (aQIV); 
Licensed MF59 -adjuvanted Trivalent Subunit 
Inact ivated Egg -derived Influenza Vaccine (aTIV -1);
MF59 -adjuvanted Trivalent Sub unit Inactivated Egg-
derived Influenza Vaccine Containing the Alternate B 
Strain (aTIV -2).
Secondary Immunogenicity Endpoints:
Characterization of immunogenicity of aQIV, aTIV -1 and aTIV -2:
The m easures of immunogenicit y of aQIV, aTIV -1 and aTIV -2 will be assessed in terms 
of HI antibodi es. Serum  HI ant ibody  titers against the 4 influenza vaccine strains will be 
used to calculate: 
GMT: Geom etric mean of HI ti ters on Day 1 and Day 22; 
GMR: The geo metric mean of the fol d increase of post -vaccinat ion HI ti ter over 
the pre -vaccination HI titer (Day 22/Day 1 ;
The percentage of subjects with a titer ≥ 1:40 at Day 1 and Day 22 ;
SCR:   the percentage of subjects with either a prevaccination HI tite r < 1:10 and 
a postvaccination HI titer ≥ 1:40 or a prevaccinat ion titer ≥ 1:10 and a ≥ 4 -fold 
increase in postvaccination t iter on Day  22.
Superiority of immunologic response for aQIV vs aTIV:
Superi ority of aQIV over aTIV -1 and aTIV -2 for ant ibody  respon se to the al ternate B 
strain will be assessed using the GMT ratio (aT IV/aQIV) and difference in SCR (aTIV –
aQIV) at Day  22. Point estimates and 95% confidence limit s will be obtained as 
described for the primary  endpoint. Superiorit y will be declared if t he upper limit of the 
two-sided 95% CI for the difference in SCR (aTIV –aQIV) is < 0 and the upper limit of 
the two sided 95% CIfor the GMT ratio (aTIV/aQIV) is < 1 for both B strains.
Interim Analysis: An interim analys is is not pl anned for this study .
Data Monitoring Committee: An independent Data Monitoring Committee will not be 
utilized for the study .Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17Version 1.0 Page 26of 104
PRO -01 TEMP 06 / Atlas No. 293620
Version No. 4/ Version Date: January 29, 20151. The invitation to participate and the informed consent process must be conducted within 10 days before the day of vaccination (Day 1) 
2. Confirm that patient has had the opportunity to ask questions and consent form(s) are signed prior to any V118_20 procedur es being performed.
3. Procedure to be performed prior to vacci nation. All eligibility criteria must be met before any study procedures (eg., blood sampling) can be performed. 
4. Phy sical examination must be performed by a qualified health care practitioner in accordance with local regulations and li censing requireme nts designated 
within the Site Responsibility Delegation Log.
5. Vaccination should occur only after the pre -dose blood sample collected.
6. After vaccinatio n, the subject will remain under medical supervision for at least 30 minutes and observed forlocal and systemic AE and unsolicited AEs. A
body temperature measurement (preferably oral) will be taken.
7. A D iaryCard , thermometer and ruler w ill be dispensed at Day 1.  Subject will receive instruction on diary completion and thermometer and ruler use. 
8. On Day 1approximately 6 hours after the vaccination or prior to going to bed at the latest , and daily thereafter through Day 7, solicited local and systemic 
adverse events including other adverse event s (i.e., body temperature measurements and use of an algesics/antipyretics) will be report ed daily by the subject in the 
DiaryCard .
9. The reminder call at Day 3 will be made by site staff to remind the subject to complete the Diary C ard. In the safety calls at Day 15, Day 91 and day 181, 
subjects will be i nterviewed by site staff using a scripted interview for collect ion of safety data. These safety data will be collected in source documents by the 
individuals performing the interviews.
10. The subject will be asked to contact the site staff if the subject experiences ILI symptomsaduring th e interval between Day 1 and Day 2 2 (i.e., up to an d 
including the day of the Day 22 blood sample). The subject should visit the site within 3 days of the onset of the ILI in order for a nasopharyngeal swab s ample 
to be t aken, however samples will be accepted if collected up to 6 days following the day of ILI onset. The sample will be sent to t he central laboratory for RT -
PCR analy sis.
a defined as at least one of the following respiratory symptoms: sore throat, cough, spu tum production, wheezing, or difficulty breathing; concurrently with at 
least o ne of the following systemic symptoms: oral temperature of >37.2°C/ 99°F, chills, tiredness, headache, or myalgia.
11. All adverse events through the day 22 visit, and medicatio ns used to treat them.
12. Any subject who terminates the study prematurely  after receiving a vaccination should have a terminat ion visit/call ( Section 5.5.1 ).Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 27of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015LIST OF ABBREVIATIONS
AE Adverse Event
AESI Adverse Event of Special  Interest
CBER Center for Bio logics Evaluat ion and Research
CDC Centers for Disease Control and Prevent ion
CI Confidence Interval
CRF Case Report Form
CRO Contract Research Organization
CSR Clinical Study  Report
DCF Data Cl arificat ion Form
DMC Data Monitoring Committee
EC Ethics Co mmit tee
EDC Electronic Data Capture
EMA European Medicines Agency
FAS Full Analysis Set
FDA United States Food and Drug Administration
GCP Good Clinical Pract ices
GMR Geom etric Mean Rat io
GMT Geom etric Mean Ti ter
GMTr Geom etric Mean Ti ter Rati o
HA Hem agglut inin
HI Hem agglut ination Inhibit ionDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 28of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015HIPAA Health Insurance Portabilit y and Accountabilit y Act
IB Invest igator’s Brochure
ICF Inform ed Consent Fo rm
ICH International Council (previously Conferen ce) on Harm onisat ion of 
Technical Requirements for Pharmaceuticals for Human Use
ILI Influenza -Like Illness
IM Intram uscular
IRB Institutional Review Board
IRT Interactive Response Techno logy
MedDRA Medical Dict ionary for Regulatory  Activities
MN Microneutralizat ion
NA Neuraminidase
NOCD New Onset of Chronic Disease
NP Nasopharyngeal
PCR Polymerase Chain Reaction
PP Per Protocol
PPS Per Protocol  Set
PV Pharmacovigilanc e
aQIV Adjuvanted Quadrivalent Influenza Vaccine
QIV Quadrivalent Influenza Vaccine
RT-PCR Reverse Transcriptase Polymerase Chain React ion
SAE Serious Adverse Event
SAP Statistical Analysis PlanDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 29of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015SC Seroconversio n
SCR Seroconversio n Rate
SDA Source Data Agreement
SOC System  Organ Class
SOP Standard Operating Procedure
aTIV Adjuvanted Trivalent Influenza Vaccine
TIV Trivalent Influenza Vaccine
WHO World Heal th Organizat ion
VSAE Vaccine Seri ous Adverse EventDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 30of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20151. BACKGROUND AND RATIONALE
1.1 Background
Influenza is an infectious disease caused by the influenza virus, an orthomyxo virus with 
two clinically relevant ty pes (ty pes A and B). The di sease is characterized by  the abrupt 
onset of respiratory  and systemic symptoms, suc h as fever, myalgia, headache, severe 
malaise, nonproductive cough, sore throat, and rhinit is(Temteand P runuske
, 2010) , and 
occurs in epidemics throughout the northern and southern hemisphere winter months in 
temperate climates. In general, influenza is reso lved within two to seven days, alt hough 
symptoms of cough and malaise may be pro longed. However, for some people, notably 
older adul ts and those wi th chronic diseases (such as pulmo nary or ci rculatory  disorders, 
metabo lic disor ders such as diabetes mellitus, renal dysfunction, or immunosuppressio n), 
influenza can exacerbate underlying medical conditions and/or lead to secondary  viral  or 
bacteri al pneum onia ( Rothberg et al. , 2008; Fiore et al . , 2009 ). During influenza 
epidemics, there i s increased m ortali ty among older adul ts (age > 65 y ears) and people 
with chroni c diseases, as well as an increase in mo rbidity and hospi talizati on because of 
influenza -associ ated com plicat ions(Fioreetal.2009; Monto 2008 ).
The abilit y of vaccinat ion to prevent influenza in older adults appears to be lower 
compared wi th younger adul ts(Osterholm, Kelley et al. ,
2012; Beyer, McElhaney et al. ,
2013) , possibly because of a less robust immune response after influenza vaccinat ion
(Goodwin, Viboud et al. ,
2006; Sasaki, Sullivan et al. , 2011). One way to increase 
immunogenicit y of influenza vaccines is through the use of adjuvants, such as the 
squalene and water emulsio n adjuvant, MF59.  Fluad, Seqirus’ trivalent seasonal 
influenza vaccine adjuvanted with MF59, has been licensed for use i n Europe since 1997 
and in the US since 2015. It has been shown to generate significant ly higher geometric 
mean hemagglut ination inhibit ion (HI) ti ters and rates of seroconversio n than a non -
adjuvanted trivalent influenza vaccine comparator in elderly subj ects(Frey et al .
, 2014).  
Trivalent influenza vaccines contain just one B strain ant igen. Influenza t ype B viruses, 
however, have separated into two dist inct genet ic lineages since 1985, Yamagata and 
Victoria
(Rota et al ., 1990) . B strains fro m either lineage m ay ci rculate simultaneously 
(Ambrose and Levin ,
2012) and cause infect ion, and mismatch may occur between 
circulat ing B strains and the strain contained in a trivalent vacc ine(Lo, Chuang et al. ,
2013). On average, influenza B strain accounts for approximately 25% of posit ive 
specimens in the US. Mismatches between the B strain in a trivalent vaccine and the 
circulat ing strain occur in approximately 5 o ut of every 10 influenza seasons
(Belshe ,
2010) . To overcome this, several quadrivalent inact ivated influenza vaccines are 
now licensed in the US, containing representative vaccine strains for both B -strain 
lineages, as well as th e H1N1 and H3N2 A subt ypes. Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 31of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20151.2 Rationale
The invest igational product (aQIV) is an MF59 -adjuvanted egg-derived subunit 
inact ivated quadrivalent influenza virus vaccine. A 0.5 mL dose is formulated to contain 
15 mcg hemagglut inin (HA) of each influenza vir us strain, including representative 
strains of both B lineages. The aQIV formulat ion is consistent with the current ly licensed 
Fluad trivalent influenza virus vaccine (aTIV), butcontains an addit ional B influenza 
strain so that the total HA concentrati on is 60 mcg HA/0.5 mL dose, from four strains.
The aim of this study  is to dem onstrate that inclusion of an addit ional B vaccine strain 
elicits an ant ibody  response to that strain and does not adversely  impact the 
immunogenicit y response against strains prev iously included in trivalent formulat ions. 
Addit ionally , the aim is to dem onstrate and confirm an acceptable safet y and tol erabilit y 
profile for the quadrivalent influenza vaccine formulat ion in the elderly population.
Data from this study  will be used to support the licensure of aQIV for the prevent ion of 
seasonal influenza in adults ≥ 65 y ears of age.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 32of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20152. OBJECTIVES
2.1 Prim ary Objective s
Co-Primary Immunogenicity Objectives:
1.To dem onstrate that vaccinat ion with aQIV elicit s an immune response that is 
notinferior to that of an aTIV con taining the same virus strains as the US 
licensed adjuvanted influenza vaccine (Fluad, aTIV -1), and an aTIV containing 
the alternate B strain (aTIV -2) am ong adul ts ≥65 years of age.
2.To assess the immunogenicit y of aQIV in ad
ults ≥65 years of age, based on the 
CBER (Center for Bio logics Evaluat ion and Research) recommendat ions.
2.2 Secondary Immunogenicity Objective s
The secondary  immunogenici ty object ives of the study are to assess the fo llowing, 
among adul ts aged ≥ 65 y ears: 
1.To characterize the immunogenicit y of aQIV, the aTIV -1 containing the same 
virus strains as the US licensed adjuvanted trivalent influenza vac cine, and the 
aTIV -2 containing the alternate B strain,by hemaggl utination inhibit ion (HI) .
2.To dem onstrate the immuno logical superiori ty of aQIV com pared to aTIV -1 and 
aTIV -2 for the B strain that is not included in each TIV vaccine separately.
2.3 Secon dary Safety Objective: 
1.To assess safet y and tol erabili ty of aQIV, aTIV -1, and aTIV -2among adults ≥65 
years o f age.
2.4 Exploratory Immunogenicity Objectives
1.To expl ore the associ ation between HI immune response after administration of 
aQIV or the aTIV -1, con taining the same virus strains as the US -licensed 
adjuvanted trivalent influenza vaccine, and the aTIV -2 containing the alternate 
B strain by baseline characterist ics.
2.Addit ional o ptional object ives include characteriz ation of the immunogenicit y 
of aQIV using other immuno logical assays (e.g., virus neutralization [MN] or 
anti-neuraminidase ant ibody assays may be performed).
Both exploratory object ives may be performed using ei ther hom ologous or heterol ogous 
strains, or both.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 33of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20153. STUDY DESIGN
3.1 Overview of Study Design
This phase 3 study  is a rando mized, double -blinded, comparator controlled, parall el 
group, m ulticenter study  of aQIV versus the US licensed 2017 -2018 adj uvanted trivalent 
influenza vaccine (Fluad, aTIV -1), and versus an adjuvanted trivalent influenza vaccine, 
aTIV -2, containing the alternate B strain.
The study  will be conducted duri ngthe 2017 -
2018 Northern Hemisphere influenza season 
in male and female adults aged 65 years and older who are healthy or have co -morbidities 
(Secti on 5.1.2) which increase their risk of co mplicati ons f rom influenza infect ion. 
Subjects will be rando mized to one of the three treatment groups in a 2:1:1 ratio. An 
Interactive Response Techno logy (IRT) system  will be used for subject randomizat ion.
Subjects will provide sero logical specimens before and after v accinat ion as well as 
complete Di ary Cards for solici ted local and systemic adverse event s. 
Each subject will have two stages of study  partici pation: Treatm entPeriod (Day  1 through 
Day 22) and Fo llow-up Peri od (Day  23 through Day  181).
Treatment Period: Day 1 through Day 22
Written inform ed consent m ust be obtained pri or to any  study -related procedures. The 
inform ed consent process may be conducted up to 10 day s before the day  of vaccinat ion 
(Day  1). Prior to vaccination on Day  1, evaluati ons will be performed and will include 
medical history , physical exam ination, and vital signs. A blood sample will be co llected 
from all eligible subjects f or influenza- specific serol ogy testing . All eligibili ty 
assessments need to be completed pri or to bl ood sample collect ion. Subjects will be 
assessed for risk of complica tions f rom influenza using the scoring system described by 
Hak ( 2004). 
All eligible subjects will then receive a dose of 0.5 mL of study  vaccine to whi ch they  
were assigned, administered intramuscularly in the deltoid muscle, pref erably  of the non -
dominant arm.
After vaccination, all subjects will remain under medical supervisio n at the study  site for 
at least 30 minutes to be monitored and evaluated for local and systemic adverse events 
(AEs).
Subjects will receive a thermo meter, a ruler and a Diary Card, al ong wi th instructi ons to 
ensure proper complet ion, and will note any occurrence of solicit ed local and systemic 
AEs, and record their oral temperatures for events occurring on Day 1 through Day  7. The 
Diary Card will only be use d to collect solicited adverse events.
A reminder telephone call will be made on Day  3 (window, Day  2 to Day  4) to remi nd the 
subject to complete the Diary  Card. Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 34of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015A scripted safet y telephone call will be made by qualified site staff on Day 15 (window: 
Day 12 to day  18) to collect any  unsolici ted AEs and any  use of  concomi tant m edicat ions: 
these will be captured in the electronic Case Report Form (CRF).
Subjects will return to the clinic on Day  22 (window, Day  19to Day  25) for a m edical 
examinat ion, and to provide a blood sample for serol ogic testing. During this visit Diary 
Cards will be collected and all unsolicit ed AEs and concomitant medicat ion use 
(occurring after vaccinat ion between Day 1 and Day 22) will be documented in the 
subject’s source records a nd captured in the CRF.
Any subject who manifests signs of an influenza -like illness (ILI, defined as at least one 
of the fo llowing respi ratory  symptom s: sore throat, cough, sputum production, wheezing, 
or difficult y breathing; concurrently wit h at l east o ne of the fo llowing systemic 
symptoms: temperature of >37.2°C/ 99°F, chills, t iredness, headache, or myalgia) during 
the may be perform ed at any  time during the Treatment Period (Day s 1
-22) will be 
evaluated by real t ime reverse transcript ion polymerase cha in react ion (RT -PCR) testing 
of a nasopharyngeal (NP) specimen for influenza. Swabs will be sent to a qualified central 
laboratory  as specified in the Clinical Invest igator Laboratory Manual. Subjects with 
onset of ILI and RT -PCR -confirmed influenza during theTreatm entPeriod (Day s 1-22) 
will be remo ved fro m the Per Protocol Set (PPS) in the immunogenicit y analyses. ILI will 
also be recorded as an adverse event.
Follow -up Period: Day 23 through Day 181
A scripted safet y telephone call will be made by qual ified site staff on Day 91 (window: 
Day 84 to Day  98) to collect only those unsolicited AEs that are: serious AEs (SAEs), 
AEs leading to study  withdrawal, new onset of chronic diseases (NOCDs), adverse events 
of special interest (AESIs); and concomitant me dicati ons associ ated wi th these events. 
A scripted safet y telephone call will be made by qualified site staff on Day 181 (window: 
Day 167 to Day  195) for assessment of SAEs, AEs leading to study  withdrawal, NOCDs, 
and AESIs; and conco mitant m edicat ions as sociated wi th these events.
An unscheduled study  visit may be perform ed as necessary  for further evaluati on of  
safet y informat ion that i s described on the telephone that is to be investigated further at 
any time during the study .
A clinical study  report wi ll present immunogenicit y and safet y data collected through the 
final evaluation (6 months fo llowing vaccinat ion, Day  181).
3.2 Study Period
Each subject should expect to participate in the study  forapproximately 6 months from 
the time o f enrollment throu gh the last study visit (Day  181 phone call) .Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 35of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20153.3 Blinding Procedures
The tri al is designed as a double- blind study . There are no vi sible differences between the 
investigat ional aQIV vaccine and the two comparator aTIV vaccines. Vaccines will be 
selected a nd administered according to the Pack ID assigned to the subjects by IRT. 
Neither the subject nor any  of the invest igative staff who are invo lved in administering 
the vaccines or clinical evaluat ion of the subject will be aware of the vaccine 
administered.
In case of an emergency , the Investi gator can disclose the subject’s assigned vaccine. The 
inform ation can be retrieved from the IRT sy stem  either via web or phone (a 24/7 backup 
service).
Except in the case of medical necessit y, a subject’s treatment sho uld not be u nblinded 
without the approval  of the Sponsor. In general, unblinding should only be performed 
when knowl edge of the assigned treatment will affect a subject’s management. In such 
instance of medical emergency, every  effort should be m ade to con tact the Sponsor prior 
to unblinding. If unblinding should occur (by  either acci dental  unblinding or em ergency  
unblinding for an SAE) prior to complet ion of the study , the Invest igator must promptly 
contact the Sponsor and document the circumstances on the appropriate forms. 
Instructi ons regarding emergency  unblinding will be provided to the Invest igator.
All personnel invo lved in performing laboratory  assays and others who are direct ly 
involved in the conduct of the trial or in the analysis of the final tr ial results will remain 
blinded to the treatment codes until at least the database has been locked for final 
analysis.
3.4 Data Collection
3.4.1 Data Collected from Subjects
The fo llowing data will be co llected fro m each subject over the duration of their study  
participat ion:
Medical History
Vaccinat ion History  
Dem ographic Information.
All unso licited AEs (fro m Day 1 through Day  22)
Adverse Events (from Day 23 through Day  181):
oAEs leading to withdrawal
oAESIsDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 36of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015oNOCDs
oSAEs
oConcomitant Medications (as defined in Sect ion 6.5)
Reason for study  terminat ion
All data collected must only  be ident ified using the Subject ID, as described in Section 
5.1.4, Randomization.
3.4.2 Tools Used for Data Collection
Data will be record ed in the DiaryCard and co llected on Case Report Forms (CRFs).
Diary Cards
Subjects will be given a paper diary  at thei r Day  1 clinic visi t to com plete. The paper 
diaries ,hereafter referred to as the Diary  Card , will be the only  source docum ent all owed 
for solici ted local and systemic adverse events (including body  temperature 
measurements), starting after the init ial 30 minute postvaccinat ion peri od at the clinic 
through Day  7.
At the Day  22 clinic visit subjects are to return t heir completed D iary Card and the site 
staff s hould review the informat ion entered with them . The foll owing addi tional rul es 
apply to documentation of safet y information collected in the DiaryCard :
1.No corrections or addit ions to the informat ion recorded by  the subject or l egal 
representative to the Diary Card will be allowed after it is delivered to the site.
2.Any blank or illegible fields on the Diary Card must be described as missing in the 
CRF.
Case Report Forms
This study  utilizes electroni c Case Report Forms (CRFs) to collect s tudy-related data 
from each subject. A qualified site staff member(s) is required to enter subject data in the 
CRFs in English based on the medical informat ion available in each subject’s source 
record.
Data should be entered into the CRF in a t imely fashi on following each subject’s clinic 
visit, study  procedure, or phone call. Each subject’s CRF casebook will be compared with 
the subject’s source records by  a Seqirus-approved study  monitor (or desi gnee) over the 
durati on of  the study  in order to ensure dat a collectio n accuracy.
The fo llowing addi tional rul es apply to documentation of Diary  Card information 
collected in the CRFs:Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 37of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20151.The site must enter all readable entries in the Diary Card into the CRF, including 
those values that may be bio logically  implausib le (e.g.,body temperature: 400°C).
2.Any illegible or implausible data should be r eviewed with the subject or legal 
representative . If an underlying so licited or unsolicited adverse event is described on 
review with the subject, this should be described in the source document and reported 
as an unso licited adverse ev ent in the Adverse Event CRF ( e.g., if the subject above 
confirms body  temperature of 40°C on the day  in which body  temperature: 400°C was 
written into his/her DiaryCard , this fever of 40°C shou ld be recorded in the Adverse 
Event CRF).
3.Any newly  described safet y informat ion (including a solicited adverse event) must not 
be written into the Diary Card and m ust be described in the study  file as a verbally 
reported adverse event. Any  adverse event r eported in this fashio n must be described 
as an unso licited adverse event and therefore entered on the Adverse Event CRF.
3.5 Collection of Clinical Specimens
The fo llowing clinical specimens are required to be collected from each subject in this 
study :
Blood at the Day  1 and Day 22 clinic visits
Nasopharyngeal swabs (as needed fro m subjects experiencing symptoms that meet ILI 
criteria from Day 1 through Day 22 )
Collect ion and processing of each specimen should b e com pleted by  a qualified si te
member and i n accordance with the study -specific Clinical Specimen Laboratory  Manual . 
Testing of clinical specimens will be performed by a Seqirus designated laboratory . Refer 
to the study -specific Clinical Specimen Laboratory Manual for additional details.
Blood Spec imens
Approximately  10 mL sample of blood will be drawn fro m all eligible subjects at Day 1 
before vaccinat ionand at Day  22. The blood volume will not exceed 10 mL at each time 
point in order to provide the necessary serum vo lume (approximately half of th e blood 
draw volume) for the serology  assays. See Section 7, Assessments for addi tional details.
The total amount of blood collected over the study  period per subj ect will be 
approximately  20mL.
Nasopharyngeal Swabs
Subjects, who from Day  1 to Day  22, experi ence symptom s meet ing the ILI criteria (ie, at 
least one of the fo llowing respi ratory  symptom s [new onset or exacerbation of pre -
exist ing condit ion]: sore throat, cough, sputum production, wheezing, or difficult y 
breat hing concurrent ly with at least one of the following systemic symptom s: tem perature Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 38of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015of > 37.2°C/ 99°F, chills, tiredness, headache, or myalgia), will have one NP swab 
collected for evaluat ion of the presence of influenza virus by RT -PCR. The NP swab will 
be collected as soon as possible within 3 days o f ILI onset, but collection up to 6 day s will 
be permitted.
3.6 Stopping/Pausing Guidelines
There are no predetermined stopping rules in this study . Subjects m ay be wi thdrawn from  
the study  according to inves tigator di scret ion as described in Section 3.8, Prem ature 
Withdrawal fro m Study .
The Sponsor can halt the study  at any  time. If the study  is halted, the Sponsor will 
prom ptly notify the health authorities and in vestigators, who will prom ptly inform the 
study  subjects and l ocal Ethi cs Committee/ Inst itutional Review Board (EC/IRB) as per 
local regul ations. F urther enro llment will only  occur after wri tten authori zation is 
provi ded by the Sponsor in consultation wit h the health authorit ies and EC/IRB, as 
appropriate.
3.7 Data Monitoring Committee
An independent Data Monitoring Co mmittee will not be utilized for the study.
3.8 Premature Withdrawal from Study
Subjects m ay withdraw at any  time, or be dropped fro m the study  at the discretion o f the 
investigator should any  untoward effects occur and/or for safet y reasons. In addi tion, a 
subject may be withdrawn by  the invest igator or the Sponsor if he/she vio lates the study  
plan or f or administrative reasons. The I nvest igator or study  coordinator m ust notify the 
Sponsor immediately when a subject has been withdrawn due to an adverse event.
The ci rcumstances above are referred to as premature withdrawal from the study , and the 
reason for premature withdrawal should be clea rly docum ented and detailed in the source 
docum entati on. The invest igator should make every attempt to evaluate the subject’s 
safet y, including reso lution of ongoing AEs, at the time of premature withdrawal. If a 
subject w ants to withdraw from the study prior to the last planned study  visit, the subject 
will be asked to be fo llowed for safet y for the duration of the study. When a subject 
withdraws, or is withdrawn, from the study , the procedures described in Section 5.5.1, 
Early Terminat ion Visit shoul d be com pleted if possible. Withdrawn subjects will not be 
replaced.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 39of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015The reasons for premature withdrawal fro m the study  include: Adverse event, death, 
withdrawal  of consent, l ost to foll ow-up, administrative reason , and protocol  deviat ion. 
These reasons are described in greater detail below.
Adverse Event
For any  subject wi thdrawn from  study  parti cipat ion prior to the pl anned Study  
Terminat ion Visit, i t is important to determine if an AE was associated with the reas on for 
discontinuing the study . Thi s AE m ust be i dentified on the AE CRF page by  indicat ing 
“Wit hdrawn fro m study  due to AE”. Any ongoing AEs at the time of study  withdrawal  
must be fo llowed until reso lution or stabilizat ion(see Secti on 7. 1, Safet y Assessments ).
Death
For any  subject wi thdrawn from  study  parti cipat ion due to death, this should be noted on 
the Study  Terminat ion CRF page and the associated SAE that led to the death must be 
reported (see Section 7. 1, Safet y Assessments ).
Withdrawal of consent
The subject (or their legally appo inted 
representative ) can wi thdraw consent for 
participat ion in the study at any t ime without penalty  or loss of benefit to which the 
subject is otherwis e ent itled. If the subject withdraw s consent forthe study , no further 
study  procedures will be performed with the subject.
If a subject withdraws consent but does not revoke the Health Insurance Portabilit y and 
Accountabilit y Act ( HIPAA )authori zation, the Sponsor will have full access to the 
subject’s medical records, including terminat ion visit informat ion. If a subject revokes 
only the HIPAA authori zation, the Sponsor will have full access to all of the subject’s 
medical records prior to the date and ti me of written revocation.
Lost to Follow -Up
For subjects who fail to show up for visits (clinic or tel ephone contacts), study  staff are 
encouraged to make at least three documented attempts to contact the subject by 
telephone and at l east one docum ented wr ittenattempt to contact the subject to encourage 
the com pletion of  study  terminati on procedures. These efforts to contact the subject 
shoul d be recorded in the source document. The termination date for the subject to be 
captured on the Study  Terminat ion CRF page is the date of the last successful contact 
(clinic visit or telephone) with the subject.
Administrative Reason
Examples for subjects withdrawn from the study  due to administrative reason can include: 
Sponsor decisio n to terminate t he study, subject meeting a pre specified withdrawal 
criterion, subject discont inuat ion for insurance issues, moving, no time, etc. This reason Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 40of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015shoul d be noted in the Study  Terminat ion CRF page and any  ongoing AEs at the time of 
study  withdrawal  must be fo llowed unt il reso lution/stabilizat ionwhenever possible .
If the clinical study  is prematurely terminated by  the Sponsor, the investigator is to 
prom ptly inform the study  subjects and l ocal EC/IRB and should assure appropriate 
therapy  and f ollow up for the subjects. All proc edures and requirements pertaining to the 
archiving of study  documents shoul d be fo llowed. All  other study  materials (study  
medicat ion/vaccines, etc.) must be returned to the Sponsor.
Protocol Deviation
A protocol deviat ion is any change, divergence, or de parture from the study  design or 
procedures of a study  protocol . In general , subjects associ ated wi th protocol  deviat ions 
may remain in the study  unless continuat ion in the study jeopardizes the subject’s healt h, 
safet y, or ri ghts.
Invest igators will apply due diligence to avoid protocol deviat ions. Und er no 
circumstances shoul d the I nvest igator con tact Seqirus or its agents, if any, monitoring the 
study  to request approval  of a protocol  deviati on, as no authori zed de viations are 
permitted. If the I nvest igator feels a change to the protocol would improve the conduct of 
the study  this m ust be considered a protocol amendment, and unless such an amendment 
is agreed upon by Seqirusand approved by the IRB/EC and health authorities it cannot be 
implemented. 
For subjects who are withdrawn fro m the study  due to receipt of an excluded 
medicat ion/vaccination or due to significant protocol non -compliance, this reason should 
be noted in the Study  Terminati on CRF page.
3.9 End of Study
Evaluat ion of the primary and secondary  immunogenici ty object ives requires the testing 
of biological samples from  the study  subjects, which can only be co mpleted after all 
samples are collected. The last samples for the analysis o f the primary and secondary  
immunogenicit y objectives will be taken at Day  22. For the purpose of this protocol, end 
of study  is defined as the complet ion of the Last Subject Last Visit (LSLV), i.e. the last 
subject’s Day  181 safet y phone call , or the com pletion of  testing of bio logical samples, to 
be achieved no later than 8 m onths after LSLV, whichever is longer.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 41of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20154. SELECTION OF STUDY POPULATIO N
4.1 Inclusion Criteria
Subjects m ust m eet all of the fo llowing inclusio n criteria to parti cipate in thi s study :
1.
Males and females ≥ 65 y ears ol d who are healthy or have co -morbidities
2.Individuals who or who se legal representative (s) have vo luntarily given written 
consent after the nature of the study  has been explained according to local 
regul atory  requi rements, pr ior to study  entry
3.Abilit y to attend all scheduled visit s and to comply with st udy procedures 
including Diary  Card completion and fo llow-up (and responding to messages and 
telephone contact). A subject or legal representati veshoul d be considered able to 
complyif the Invest igator judges that the s ubject will co mplete the Diary Card 
when applicable, return for all the fo llow-up visi ts, and be available for tel ephone 
calls as scheduled in the study
4.2 Exclusion Criteria
If one or m ore of the fo llowing exclus ion criteria are m et, the subject will be ineligible to 
take part in this study :
1.History  of behavi oral or cogni tive impairment or psychiatric condit ion that, in the 
opinio n of the Invest igator, may interfere with the subject's abilit y to parti cipate in
thestudy
2.History  of any medical  condi tion considered an ad verse event of special interest
3.Progressive or severe neuro logical disorder, sei zure di sorder, or hi story of 
Guillain -Barré syndro me
4.Hypersensi tivity, incl uding allergy , to any  com ponent of vaccines, medicinal 
products or medical equipment whos e use is foreseen in this study
5.Clinical condit ions representing a contraindicat ion to intramuscular vaccinat ion 
and blood draws, including bleeding diathesis, or any other condit ion that m ay be 
associ ated with prolonged bleeding
6.Abnorm al function of the immune system result ing fro m: 
a. Clinical condit ionsaffecting the immune system (e.g. HIV infect ion,
  agammaglo bulinemia)
b. Sy stemic administrati on of  corti costeroi ds (PO/IV/IM) at a dose 
equivalent to 20 mg/day of prednisone for m ore than 14 consecut ive days 
within 90 days pri or to inform ed consent
c. Administration of ant ineoplast ic and immuno modulating agents ( eg,
TNF α -antagonists or anti -B cell ant ibodies) or radiotherapy  within 1 y ear
prior to inf ormed consentDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 42of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20157.Receipt of immunoglobulins or any  blood products wi thin 180 days pri or to 
inform ed consent
8.Receipt of an investigat ional or nonregistered medicinal product within 30 days 
prior to inform ed consent or before complet ion of the safet y follow-up period in 
another study , orwho are unwilling to refuse participat ion in another clinical 
study  at any  time during the conduct of this study  (note: concomitant participat ion 
in an observational study  not invo lving drugs, vaccines, or medical de vices, is 
acceptable)
9.Study  personnel or immediate family members (brother, sister, child, parent), the 
spouse of personnel with direct involvement in the study
10.Receipt of any  influenza vaccine within 6 months prior to enrol lment in this study ,
or plan to receive infl uenza vaccine prior to the Day  22 bl ood collection
11.Receipt of any  inactivated non-influenza vaccine 14 day s or live -attenuated 
vaccine 28 day s prior to enro llment in this study  or plans to receive any  other non -
influenza vaccine within 28 da ys from study  vaccinat ion
12. Fever at the time of screening, defined as oral temperature ≥38.0 degrees Celsius 
(≥100.4° F). Enrol lment coul d be considered if fever is absent for 72 hours
13.Signs or symptom s of acute infect ion at the time of screening. Enro llment coul d 
be defe rred if signs and s ymptom s are absent for 72 hours
14.Fatal  prognosis of an underlying medical condit ion (<12 m onths life expectancy)
15.Any other clinical condit ion that, in the opinion o f the Invest igator, might interfere 
with the resul ts of the study  or pose addit ional risk to the subject du e to 
participat ion in the study
4.3 Criteria for Delay of Vaccination
There m ay be instances when individuals meet all eligibilit y criteria for vaccinat ion yet 
have a transient clinical circumstance which may warrant delay of vaccination: body  
temperature el evati on [≥38.0°C ( ≥ 100.4° F) within 3 days prior to intended study  
vaccination], or use of antipyret ics and/or analgesic medicat ions wit hin 24 hours prior to 
vaccination. Under such circumstances, a subject may be consi dered eligible for study  
enrollment after the appropriate window for delay has passed and inclusio n/exclusio n 
criteria have been rechecked, and if the subject is confirmed to be eligible.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 43of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20155. STUDY PROCEDURES
The sect ions that fo llow provi de an overview of the procedures that are to be fo llowed in 
enrolling, evaluat ing, and fo llowing subjects who participate in this clinical study . Visits 
can be eit her clinic visits or safet y follow
-up tel ephone calls, as specified in the Table 
below and in the Time and Events Table .
Table 5 Study Procedures
Visit Category Procedures
Prevaccination Clinic Visit Section 5.1 describes procedures to be followed 
prior to study vaccination: informed consent, 
screening, enrol lment, and randomization
Vaccinatio n Clinic Visit Section 5.2 describes proce dures to be followed 
during the vaccination clinic visit : vaccination, post -
vaccination procedures, and post -vaccina tion 
reminder call
Postvaccination Visit /Call (s) Section 5.3 describes follow -up clinic visits and 
safety follow -up calls
Unscheduled Visit(s) Section 5.4 descr ibes possible procedures to be 
followed at unscheduled clinic visit
Study Termination Visit Section 5.5 describes procedures to be followed at 
the last study visit for a subject (may include early 
termination visi t)
5.1 Prevaccination Clinic Visit(s)
This sect ion describes the procedures that must be performed for each potential subject 
prior to vaccination, including obtaining informed consent, screening, enro llment and 
rando mizat ion.
5.1.1 Informed Consent
"Informed consent" is the voluntary  agreem ent of  an individual or his/her legal 
representative (s) to parti cipate in research. Consent must be given with free will o f 
choice, and without undue inducement. The individual must have sufficient knowledge 
and under standing of the nature of the proposed research, the anticipated risks and 
potenti al benefi ts, and the requi rements of the research to be able to make an informed 
decisio n.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 44of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Informed consent of the subject fo llowing l ocal IRB/EC gui dance must be obtained 
before conducting any  study -specific procedures ( i.e., all of the procedures described in 
the protocol). The process of obtaining informed consent should be documented in the 
subject source document in addit ion to m aintaining a copy  of the si gned and dated 
informed consent. Addit ional specifics regarding the informed consent and assent 
processes are located in Section 13.2, Informed Consent Procedures .
If a subject is unable to read, an impart ial witness shoul d be present duri ng the enti re 
inform ed consent discussio n. An impartial wit ness is defined as a person who is 
independent fro m study  conduct, who cannot be unfairly influenced by those involved 
with the study , who attends the informed consent process if the subje ct or the subject's 
legally acceptable representative cannot read, and who reads the informed consent form 
and any  other wri tten inform ation supplied to the subject. After the written informed 
consent form and any  other wri tten informat ion to be provided t o subjects, is read and 
explained to the subject or legal representative and after the subject or legal representative
has verbally consented to the subject’s part icipation in the study  and, if capable of doing 
so, has signed and personally  dated the infor med consent form, the witness should sign 
and personally date the consent form. By  signing the consent form, the witness attests that 
the informat ion in the consent form and any other written informat ion was accurately 
explained to, and apparently understo od by , the subject or legal representative and that 
inform ed consent was freely given by the subject or legal representative . 
5.1.2 Screening
After an individual has consented to participate in the study  and inform ed consent is 
signed, that individual wil l be given a unique Screening Number manually  created by  the 
Invest igator. The subject’s unique Screening Number will be documented in the 
Screening and Enro llment log. The eligibilit y of the subject will  be determined based on 
the inclusio n and exclusio n criteria listed in Section 4, Select ion of Study  Popul ationand 
evaluated during this screening procedure.
Prior to study  enrol lment, demographic data will be collecte d fro m the subject, including: 
age, sex, race, ethnici ty, height and weight, prior influenza vaccinat ion, com orbidi ty,and 
risk of co mplications from influenza indicated by a calculated score. The risk assessment 
which incorporates medical co morbidity among other baseline characterist ics is a 
validated predic tor of  risk of co mplications fro m influenza in subjects ≥65 years of age 
(Hak, 2004) (see Table 5.1.2 -1, Prediction Rule for Estimat ing the Probabilit y of 
Hospitalization Due to Pneumonia or Influenza and Death Due to Any Cause ). Using this 
model, a score of <50 is considered low risk and a score of ≥ 50 is considered high risk.
Determinat ion of pre -exist ing medical condit ions, for the purpose of calculat ing the risk 
score, should be made by  the invest igator based on his or her clinical judgment. A list of Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 45of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015medica l condi tions are presented in Appendix 1 as examples for the Invest igator to 
facilitate the complet ion of the co -morbidity section of the risk score.
Table 5.1.2 -1:         Prediction Rule for Estimating the Proba bility of Hospitalization 
Due to Pneumonia or Influenza and Death Due to Any Cause (Hak 2004)
Characteristic Scor ea
Age, years
<70 0
70-74 14
75-79 28
80-89 42
≥90 56
Sex
Female 0
Male 9
Outpatien tvisitsdurin gthepreviou syearb
0 0
1-6 11
7-12 22
>13 33
Previou shospitalizatio ndue topneumoni a or influenza
No 0
Yes 63
Comorbidit yc
Pulmonar ydisease 18
Hear tdisease 6
Rena ldiseas e orrenal tran splant 12
Dementi a orstroke 22
Non-hematologica landhematologica lcancer 48Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 46of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Notes:aTheprognosti cscorefor a givensubjec tcan be obtaine d by addin gthescoresforeachapplicable 
characteristic.bScheduled and unscheduled f ace-to-face visits with aphysician or other health -care 
providers, including annual examinations, or visits to urgent care and emergency departments cPre-existin g
medica lcondition s ofeligibl esubject s will bescore dfollowin gjudgmen t bytheInvestigator. Appendix 1
provide s alist ofcondition swithexample s toprovideguidanc e tothe Investigator.
Only the total risk score will be recorded in the CRF ; pre-exist ing medical condit ions 
shoul d be recorded in the source documentation . The risk s core will be collected for each 
subject, but will not be used to stratify treatment. 
Medical history  will be collected, including but not limited to any  medical history  that 
may be relevant to subject eligibilit y for study  participat ion such as prior vacc inations, 
concomitant medicat ions, and previous and ongoing illnesses or injuries. Relevant 
medical history  can also include any  medical  history  that contributes to the understanding 
ofthe risk score and of an adverse event that occurs during study  partic ipation, if i t 
represents an exacerbat ion of an underlying disease/pre -exist ing problem.
Review of systems is a structured interview that queries the subject or legal representati ve
as to any  com plaint s the subject has experienced across each organ system. This will be 
perform ed before enrol lment and used to guide physical examinat ion.
If applicable, prior and concomitant medicat ions or vaccinat ions taken prior to start of 
study  shoul d be collected (refer to Section 6.5, Pri or and Concomitant Medicat ions and 
Vaccines for further details).
Collect ion of vital signs is to be performed: heart rate, blood pressure, respiratory  rate and 
prevaccinat ion body  temperature (preferably oral). If body  temperature i s ≥38.0°C (or 
≥100.4°F) at the time of screening, vaccination must be postponed until 3 days after the 
fever has resolved (see Section 4.3, Cr iteria for Delay of Vaccinat ion).
Measure height and weight. Measurement and recording of vital signs, height, weight and 
body  temperature, mustbe conducted by  a trained healt h care professio nal.
A general physical examinat ion is to be performed by  a qua lified healt h care practit ioner. 
“Qualified healt h care practitioner” refers to any  licensed healt h care professio nal who is 
permitted by  institutional policy  to perf orm physical  examinat ions and who is ident ified 
within the Study  Staff Si gnature Log.
Thedata described above will be wri tten in the source document (see Section 9.1, Source 
Docum entati on). Shoul d the physical assessment reveal any abnormal values or events, 
these m ust be docum ented as part of medic al history .
Prior to vaccinati on, approximately 10mL o f blood will be drawn fro mall subjects for 
immunogenicit y testing (see Section 3.5, Collect ion of Clinical Specimens ).Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 47of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015In the event that the individual is deter mined ineligible for study  parti cipat ion, he/she is 
considered a screen failure. The reason for screen failure must be documented in the 
Screening and Enrol lment log. If the individual is determined to be eligible for the study , 
he/she will be enro lled int o the study .
5.1.3 Enro llment
After signing the informed consent form, if an individual is determined to be eligible for 
study  participati on, the investi gator or del egate will enroll the subject andenter subject 
inform ation into the Interactive Response Technology  (IRT) system .
5.1.4 Randomization
Enrolled subjects will be rando mized in the IRT system and autom atically assigned a 
unique Subject ID. The Subject ID will be the subject’s unique ident ificat ion number for 
all CRFs and associated study  documen tation that will be used for duration of the study . 
After rando mizat ion, the Screening Number ceases to be used and remains in the 
Screening and Enrol lment Log only. The list of randomizat ion assignments is produced 
by the IRT service provider and approved by Seqirus or del egate.
Subjects will be rando mized in a 2:1:1 ratio to aQIV, aTIV -1, and aTIV -2. 
If for any  reason, after si gning the inform ed consent form  (ICF), the subject who is 
eligible and enro lled fails to be rando mized, this is called a rando mization failure. Further 
guidance is provided in the CRF Instructions. The reason for all rando mizat ion failures 
shoul d be recorded in the Screening and Enrol lment Log and in the source document as 
specified in the Source Data Agreement (SDA). The informat ion on subjects who are 
rando mizat ion failures should be kept dist inct from subjects who are screen failures, as 
described in Section 5.1.2, Screening.
If for any  reason, after randomizat ion the subject fails to undergo treatment, this is an 
Early Terminat ion and the reason should be recorded in source document as specified in 
the SDA. The informat ion on these Early Terminatio n subjects should be kept dist inct in 
the source documentation from rando mizat ion failures.
5.2 Vaccination Clinic Visit(s)
Please refer to Time and Events Table 2. Vaccination will be performed on Day  1 using 
the vaccine ident ified by the assigned Pack ID. The Day  1 serol ogy sample must be taken 
prior to vaccination.
After complet ing the prevaccinat ion procedures as described in Section 5.1 ,
Prevaccinat ion Clinic Visit(s) ,the vaccine will be administered to the subject according to Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 48of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015the procedures described in Section 6.3, Vaccine Preparation and Administration . Prior to 
administration of each vaccinat ion, it shoul d be confi rmedthat the subject i seligible for 
vaccination and does not m eet any  criteria for delayi ngstudy  vaccinat ionas described in 
Section 4, Selection of Study  Popul ation.
5.2.1 Postvaccination Procedures
The fo llowing post vaccinat ion procedures will be performed on D ay 1.   
Observation Period
After vaccination, the subject will be observed for at least 30 minute s for unsolicited 
adverse events, solicited adverse events, and a body temperature measurement (preferably 
oral) will  be taken . During this observat ion peri od, the subject shoul d be trained on how 
to use the thermo meter and the ruler provided ,how to m easure local solici ted adverse 
events , and how to report sy stemic so licited events (see Section 7.1.1, Solicited Adverse 
Events ). All safety  data collected during this time should be recorded in the subject’s 
sourc e document.
Diary Card Training
A Diary  Card will be used in this study  to docum ent solicited adverse events from Day 1 
to Day  7. The Diary Card is the only source for collect ion of these data; therefore, it is 
critical that th e subject completes the DiaryCard correctly . The subject shoul d be trained 
on how and when to co mplete each field of the Diary Card .The Diary Card shoul d be 
completed on a daily  basis , pref erably  in the evening, and the entries should be written 
clearly  in pen. See addi tional rules in Section 3.4.2, Tool s Used for Data Collect ion.
The subject or legal representative shoul d be trained on how to self -measure l ocal 
solicited adverse events and body  temperature. The m easurement of solicited local 
adverse events is to be performed using the ruler provided by the site.
The subject or legal representative shoul d be instructed how to perform body  temperature 
measurement using the thermo meter provi ded by  the si te. Tem perature should be checked 
at least da ily; if the subject feels unusually hot or cold during the day , the subject or legal 
representative shoul d make addit ional measurement of body  temperature. If the subject 
has fever, the highest body  temperature observed that day  should be recorded in the D iary
Card .
Diary Card training should be directed at the individual (s)who will perform the 
measurements of adverse events and who will enter the inform ation into the DiaryCard . 
In some situations, the Diary  Card may be co mpleted by  som ebody  other than th e subject 
or legal representative (except study  site personnel). If a person other than the subject or 
legal representative enters information into the DiaryCard , the reason that the subject 
cannot com plete thei r own Diary Card and the person’s identit y and rel ationship to the Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 49of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015subject must be documented in the DiaryCard . Any  individual tha t makes entri es into the
DiaryCard must receive traini ng on com pletion of the Diary Card at the time of the visit. 
This training must be documented in the subject’s sou rce.
The same individual should co mplete the Diary Card throughout the course of the study .
Plan Next Study Activities
The site should schedule the next study  activit y with the subject or legal representative . It 
is reco mmended for the site to already sche dule in advance the remaining upco ming study  
activit ies.
Discharge
The subject or legal representative shoul d be reminded to contact the site if there are any  
questions, and to contact the site immediately (or as soon as the subject is medically  
stable) if the subject has a medical condit ion that leads to a hospitalizat ion or an 
emergency room  visit or to a vi sit to/by  a doctor or is otherwise of concern.
The subject or legal representative will be reminded to contact the site immediately if the 
subject exp eriences symptom s meet ing ILI criteria in order to have a NP swab co llected 
for evaluat ion of the presence of influenza virus. If anti- viral medications (eg, 
neuraminidase inhibitors) are prescribed it is recommended that an NP swab be obtained 
prior to th e first dose.
5.2.2 Postvaccination Reminder Call
Reminder calls are not intended to be an interview for collect ion of safet y data. If the 
subject wishes to describe safety  information, thi s inform ation shoul d only be collected 
by a qualified healthcare p rofessional at the si te, and the safety  data described must be 
written dow n in the subject’s source documentation and CRF .
Diary Card Day 3 Reminder Phone Call
Subjects will receive a diary  reminder call on Day 3. The purpose of this call is to remind 
the subject or legal representative about com pletion of the DiaryCard. The call fo llows 
the Diary Card Reminder Phone Call Script provided to the site. The subject or legal 
representative shoul d be reminded to contact the site via the telephone number provide d 
in the informed conse nt to discuss medical questions .
5.3 Postvaccination Clinic Visit and Safety Calls
A postvaccination clinic visit will be performed on Day  22. Post vaccinat ion Safety Calls 
will be performed on Day 15, Day  91, and D ay 181.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 50of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20155.3.1 Follow-up Clinic Visit
At the clinic visit on D ay22, the DiaryCard will be reviewed and collected. No changes 
to the informa tion recorded wi thin the Diary  Card are permissi ble. For details on the 
Diary Card see Section3.4.2, Tools Used for Data Collect ionand Section 
5.2.1, Postvaccinat ion Procedures . The subject or legal representative will be interviewed 
to determine if any unso licited adverse events (including S AEs, ILIs, NOCDs, AEs 
leading to withdrawal and AESIs) occurred and if any conco mitant m edicati ons or 
vaccines were taken/received during the time since the last clinic visit. This interview will 
follow a scri pt whi ch will  facilitate the collect ion of rele vant safet y informat ion. The 
qualified healthcare professio nal reviewing these data will discuss the symptoms (if any) 
reported by  the subject and will determine if any  addi tional diagnoses and/or adverse 
events are present. All adverse events reported by  the subject or legal representative at 
this follow-up clinic visit must be recorded in the subject's source document and on an 
Adverse Events CRF, as specified in Section 7.1, Safet y Assessment , and not written o n 
the scri pt used for the interview.
During the Day  22 clinic visit, the subject will be asked whether he or she was 
hospi talized or was evaluated at an emergency room or a physician’s office for any  illness 
since the site’s last contact with the subject. If an SAE has been ident ified by the site staff 
during the interview which has not previously been reported by  the subject, this SAE will 
be reported by  the si te wi thin 24 hours to Seqirus or delegate. Any  addi tional relevant 
medical history  will be record ed as needed.
During the Day  22 clinic visit, an ILI assessment will be performed to determine if 
symptoms of ILI are present. Potential ILI symptoms will be documented in the subject’s 
source records. If the onset of the ILI is 6 day s or less before the v isit, a NP swab should 
be co llected fro m the subject for influenza testing and study  staff will  docum ent the ILI 
on an Adverse Event and ILI CRF (see procedures described in Section 5.4, Unscheduled 
Visits).
During the Day 22 clinic visit, a brief symptom -directed phy sical examinat ion will be 
perform ed by  a qualified healt h care practit ioner according to symptoms the subject has 
reported. This physical examinat ion will include an examinat ion of organ sy stems that are 
considered relevant by  the invest igator based on review of the subject’s reported adverse 
events, and conco mitant m edicat ion use. This assessment may include measurement of 
vital signs (respi ratory  rate, bl ood pressure and heart rate), body  temperatur e (preferably 
oral) and a check of general appearance. The physical assessment must be performed by  
the invest igator or designee of the invest igator, who is qualified to perform a physical 
assessment in accordance with their inst itutional policy . Measureme nt and recording of 
vital signs and body  temperature m ay be conducted by  a trained healt h care professio nal. 
Corresponding informat ion is documented in the subject’s source document and CRF (s).Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 51of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015During the Day  22 follow-up clinic visit, approximatel y 10 ml of blood will  be drawn 
(see Section 3.5, Collect ion of Clinical Specimens ).
The site should also schedule the next study  activity, the Day  91 safet y call, with the 
subject. It is recommended for the site to also sche dule in the rem aining upcoming study  
activit ies whenever possible.
At the Day  22 follow-up clinic visit, t he subject will receive a written reminder of the 
next planned study  activit y. The subject or legal representative will be reminded to 
contact the sit e immediately (or as soon as the subject is medically stable) if the subject 
has a m edical condit ion that l eads to a hospi talizat ion, or is otherwise of concern.
5.3.2 Safety Follow -up Phone Calls
Safety follow-up calls will be performed on Day 15, D ay91, and D ay 181.
Safety follow
-up calls are calls made to the subject by  a qualified healt hcare professio nal 
designated on the site delegation log. These calls will fo llow a script which will facilitate 
the collect ion of relevant safet y informat ion. The subj ectwill be inte rviewed according to 
the scri pt.
On Day  15, informati on will  be collected regarding all unso licited adverse events and 
concomitant medicat ions or vaccinat ions associated with those events. Safet y follow-up 
calls performed on Days 91 and 181 will co llect informat ion relating to a subset of 
unso licited adverse events including SAEs, adverse events of special interest (AESIs), 
AEs leading to withdrawal, new onset of chronic disease (NOCD), and conco mitant 
medicat ions or vaccinat ions associated with those events. All safety  informat ion 
described by the subject must be written down in a designated location within the source 
docum ent and not written on the script used for the telephone call.
The subject will be asked as to whether he or she was hos pitalized or was evaluated at an 
emergency room  for any  illness since the site’s last contact with the subject. If an SAE 
has been ident ified by the site staff during the interview which has not previously been 
reported by  the subject, this SAE will be reported by the site within 24 hours to Seqirus or 
delegate. Any  addi tional rel evant m edical history  will be reported to Seqirus or delegate 
and recorded as needed.
On Day  15, if the subject reports during the phone contact that symptom s are present 
consisten t with an ILI, the subject will be asked to visit the site for further evaluat ion and 
potenti al NP swab taking. An NP swab should be collected, for evaluat ion of the presence 
of influenza virus, preferably within 3, but up to 6, day s after the first day  ofonset of ILI 
symptoms. See procedures described in Section 5.4, Unscheduled Visits .
On Day  15, t he subject will be reminded to contact the site immediately if the subject 
experiences symptoms meet ing ILI criter ia to have a NP swab collected for evaluat ion of Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 52of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015the presence o f influenza virus. If anti -viral medicati ons ( e.g., neuraminidase inhibitors) 
are prescribed it is recommended that an NP swab be obtained prior to the first dose.
The subject will receive a re minder of the next planned study act ivity. The subject will be 
reminded to contact the site immediately (or as soon as the subject is medically stable) if 
the subject has a medical condit ion that l eads to a hospitalization or an emergency  room  
visit or to a visit to/by a doctor or is otherwise of concern.
5.4 Unscheduled Visits
An unscheduled visit describes a non- routine study visit triggered by a specific event. 
These could include ant icipated or unant icipated adverse events or intervent ions.
5.4.1 Subj ects Meeting Influenza -Like -Illness Criteria
Clinic Visit –Obtaining NP Swab
Subjects will be asked to come to the site for an unscheduled clinic visit when 
experiencing symptoms meet ing the ILI criteria from Day 1 through Day  22. The visit 
shoul d occur a s soon as possible wit hin 3, but up to 6, day s after the first day  of onset of 
ILI symptom s. During the visit the fo llowing procedures should be carried out:
Assess ILI symptoms and record associated medication. Document any anti -viral 
medicat ion use fro m the first day  of onset of ILI symptom s
Collect a NP swab for evaluat ion of the presence of influenza virus fo llowing the 
procedures for collect ing, processing and shipping as described in the Lab Manual
Evaluate the subject’s body  temperature (preferably  oral), heart rate, respiratory  rate 
and blood pressure and perform a sympto m-directed physical examinat ion
Record the ILI and related informat ion, in the source documents and in the CRF (ILI-
report and adverse events sect ion)
Schedule next study  activit y
5.5 Study Termination Phone Call 
The study  terminat ion visit (call) will occur on D ay 181. The te rminat ion visit will be a 
telephone call. The date of terminat ion is the d ate of the l ast contact (clinic visit or 
telephone call) in which the subject’s heal th status was assessed or, in cases where the 
subject does not agree to any  further safet y follow
-up, it is the date consent is withdrawn. 
This date should be recorded on the terminat ion CRF page. For visit procedures to be Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 53of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015perform ed for a subject whose pl anned study  partici pation ends prematurely, please see 
Section 5.5.1, Early  Terminat ion Visit .
The terminat ion telephone call will co llect information relat ing to a subset of unsolicit ed 
adverse events includin g SAEs, adverse events of special interest (AESIs), AEs leading to 
withdrawal , new onset of chronic disease (NOCD), and concomitant medications or 
vaccinations associated with those events. All safety informat ion described by the subject 
must be written do wn in a designated location wit hin the source document and not written 
on the script used for the telephone call.
The subject will be asked as to whether he or she was hospitalized or was evaluated at an 
emergency room  for any  illness since the site’s last contact with the subject. If an SAE 
has been ident ified by the site staff during the interview which has not previously been 
reported by  the subject, this SAE will be reported by  the si te wi thin 24 hours to Seqirus or 
delegate. Any  addi tional rel evant m edical history  will be reported to Seqirus or delegate 
and recorded as needed.
The site will complete the terminat ion CRF page and this will mark the complet ion of the 
subject’s participat ion in the study .
5.5.1 Early Termination Visit
When a subject is wi thdrawn from  treatm ent or wi thdraws fro m the study , the 
Invest igator will notify the Sponsor and, when possible, will perform the procedures 
listed below. The reason(s) for the early terminat ion will be included in the subject’s 
source documentation. If th e Early  Terminat ion Visi t is a tel ephone call, collect as much 
inform ation as possible. Early  Terminat ion Visit s include subjects who were randomized 
but not treated.
At the clinic visit or during the telephone call, the same procedures will be performed a s 
during the study  terminat ion visit, see Section 5.5 Study  Terminat ion Visit, if possible. 
In addit ion, the fo llowing procedures will be performed:
Collect and review the DiaryCard , if applicable
Review the su bject’s safet y data (if co llection o f these was in progress at the time of 
study  terminat ion)
The site will complete the terminat ion CRF page and this will mark the complet ion of the 
subject’s participat ion in the study .Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 54of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20156. TREATMENT OF SUBJECTS
All vacci nes associ ated wi th this study  are to be stored separately  from other vaccines and 
medicat ions in a secure location under appropriate storage condit ions wit h temperature 
monitoring. All vaccines associated with this study must be checked for expiration 
date prior to use. Expired vaccines must not be administered to subjects.
6.1 Study Vaccine s
The term  ‘study  vaccine’ refers to those vaccines provided by the Sponsor, which will be 
evaluated as part of the study  object ives. The study vaccines specific to th is study are 
described below. All three influenza vaccines are made similarly, with the except ion of 
the influenza strains included.
Investigational Vaccine: aQIV
An approximately 0.5 mL dose of aQIV (quadrivalent MF59C.1 adjuvanted influenza 
vaccine) cont ains nominally 15 mcg of h emaggl utinin (HA) of each of the 2 influenza 
type A strains and each o f the 2 influenza t ype B strains for a total of 60 mcg of HA in the 
vaccine. The strain composit ion is that recommended by  the World Heal th Organizat ion
for the 2017- 2018 Northern Hemisphere influenza season ( WHO , 2017 )for quadri valent 
vaccines . The full co mposit ion of the vaccine is reported in Table 6.1 -1.
Table 6.1- 1:           aQIV Vaccine Composition
Names of Ingredients Quantity per dose* Function
Active   Ingredients
Hemagglutinin (HA) and neuraminida se (NA) 
antigens from the influenza virus strains 
recommended by WHO for the manufacture of 
influenza vaccine for 2017 -2018 season
A/ Michigan/45/2015 ( H1N1) 
A/ Hong Kong/4801/201 4 (H3N2)
B/ Phuket/3073/2013 (Yamagata lineage)
B/ Brisbane/60/2008 (Victoria lineage)nominally 15mcg
HA/strainActive ingredientDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 55of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Names of Ingredients Quantity per dose* Function
Adjuvant 
Squalene 
Polysorbate 80
Sorbitan trioleate
Sodium citrate
Citric acid9.75mg
1.175mg
1.175mg
0.66mg
0.04mgOilphase
Surfactant 
Surfactant
Buffer
Buffer
Other Ingredients 
Sodium chloride 
Potassium chloride
Potassium dihy drogen phosphate
Disodium phosphate dehydrate
Magnesium chloride hexahydrate 
Calcium chloride dihydrate
Water for injection4.00mg
0.10mg
0.10mg
0.67mg
0.05mg
0.06mg
up to 0.50mLIsotonic aid 
Buffer 
Buffer
Buffer 
Stabiliser 
Stabiliser
Diluent
**
Volume of Formulation 0.5mL
Appearance Liquid, milky-wh ite emulsion
Vaccine Presentation Prefilled syringe
*  thequantitie sindicat ed in thistablereflec ttheamoun t in a 0.5 mL dose.
**residue s ofspecia lrelevance :bariu msulfate,cetyltrimethylammoniu mbromid e(CTAB) , chicken
  proteins, such asovalbumin ,formaldehyde ,kanamyci nandneomyci nsulfate.
US-licensed Comparator Vacci ne: Fluad, aTIV-1
An approximately 0.5 mL dose of aTIV -1(trivalent MF59C.1 adjuvanted influenza 
vaccine) contains no minally 15 mcg of h emaggl utinin (HA) of each of the 2 influenza 
type A strains and one influenza ty pe B strain for a total of 45 mcg of HA in the vacc ine. 
The strain co mposit ion is that recommended by the World Heal th Organizat ion for the 
2017 -2018 Northern Hemisphere influenza season ( WHO , 2017) f or trivalent vaccines. 
The full co mposit ion of the v accine is reported in Table 6.1-
2.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 56of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Table 6.1- 2:           aTIV -1 Vaccine Composition
Names of Ingredients Quantity per dose* Function
Active   Ingredients
Hemagglutinin (HA) and neuraminida se (NA) 
antigens from the influenza virus strains 
recommended by WHO for the manufacture of 
influenza vaccine for 2017 -2018 season
A/ Michigan/45/2015 (H1N1) 
A/ Hong Kong/4801/2014 (H3N2)
B/ Brisbane/60/2008 (Victoria lineage)nominally 15mcg
HA/strainActive ingredient
Adjuvant 
Squalene 
Polysorbate 80
Sorbitan trioleate
Sodium c itrate
Citric acid9.75mg
1.175mg
1.175mg
0.66mg
0.04mgoilphase
Surfactant 
Surfactant
Buffer
Buffer
Other Ingredients 
Sodium chloride 
Potassium chloride
Potassium dihy drogen phosphate
Disodium phosphate dehydrate
Magnesium chloride hexahydrate 
Calcium chloride dihydrate
Water for injection4.00mg
0.10mg
0.10mg
0.67mg
0.05mg
0.06mg
up to 0.50mLIsotonic aid 
Buffer 
Buffer
Buffer 
Stabiliser 
Stabiliser
Diluent
**
Volume of Formulation 0.5mL
Appearance Liquid, milky-wh ite emulsion
Vaccine Presentation Prefilled syringe
*  thequantitie sindicate d inthistablereflec ttheamoun t in a 0.5 mL dose.
**residue s ofspecia lrelevance :bariu msulfate,cetyltrimethylammoniu mbromid e(CTAB) , chicken   
     proteins,such asovalbumin ,formalde hyde,kanamyci nandneomyci nsulfate.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 57of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Comparator Vaccine Containing the Alternate B strain: aTIV -2
An approximately 0.5 mL dose of aTIV -2 (a trivalent MF59C.1 adjuvanted influenza 
vaccine) contains no minally 15 mcg of h emaggl utinin (HA) of each of the 2 in fluenza 
type A strains and one influenza ty pe B strain for a total of 45 mcg of HA in the vaccine. 
The strain co mposit ion is that recommended by the World Heal th Organizat ion for the 
2017- 2018 Northern Hemisphere influenza season ( WHO , 2017) f or trivalent vaccines. 
for the A strains, but the one B strain included in this vaccine is the second influenza B 
strain recommended for inclusio n in quadrivalent vaccines (ie, the alternate B strain). The 
full co mposit ion of the vaccine is repo rted in Table 6.1 -
3.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 58of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Table 6.1- 3:           aTIV -2Vaccine Composition
Names of Ingredients Quantity per dose* Function
Active   Ingredients
Hemagglutinin (HA) and neuraminida se (NA) 
antigens from the influenza virus strains
recommended by WHO for the manufacture of 
influenza vaccine for 2017-2018 season
A/ Michigan/45/2015 (H1N1) 
A/ Hong Kong/4801/2014 (H3N2)
B/ Phuket/3073/2013 (Yamagata lineage)nominally 15mcg
HA/strainActive ingredient
Adjuvant 
Squalene 
Polysorbat e 80
Sorbitan trioleate
Sodium citrate
Citric acid9.75mg
1.175mg
1.175mg
0.66mg
0.04mgoilphase
Surfactant 
Surfactant
Buffer
Buffer
Other Ingredients 
Sodium chloride 
Potassium chloride
Potassium dihy drogen phosphate
Disodium phosphate dehydrate
Magnesium chloride hexahydrate 
Calcium chloride dihydrate
Water for injection4.00mg
0.10mg
0.10mg
0.67mg
0.05mg
0.06mg
up to 0.50mLIsotonic aid 
Buffer 
Buffer
Buffer 
Stabiliser 
Stabiliser
Diluent
**
Volume of Formulation 0.5mL
Appearance Liqui d, milk y-wh ite emulsion
Vaccine Presentation Prefilled syringe
*  thequantitie sindicate d inthistablereflec ttheamoun t in a 0.5 mL dose
**  residue s of specia lrelevance :bariumsulfate,cetyltrimethylammoniu mbromid e(CTAB) , chicken   
      proteins,such asovalbumin ,formaldehyde ,kanamyci nandneomyci nsulfateDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 59of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20156.2 Non-Study Vaccines
Not applicable.
6.3 Vaccine Preparation and Administration
The I nvestigator or designee will be responsible for oversight of the administration of 
vaccine to subj ects enro lled in the study  according to the procedures stipulated in this 
study  protocol and the Pharmacy Manual . All vaccines will be administered only  by 
personnel who are qualified to perform that funct ion under applicable local laws and 
regul ations forthe specific study  site.
Detailed vaccine preparat ion and administration instructions will be provided to 
investigators prior to study  start.
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING STUDY VACCINE:
Prior to vaccinati on, subjects m ust be determined to b e eligible for study  vaccinat ion and 
it must be clinically  appr opriate in the j udgment of the I nvest igator to vaccinate. 
Eligibilit y for vaccinati on pri or to fi rst study vaccine administration is determined by 
evaluat ing the entry  criteria outlined in prot ocol Section4.1, Incl usion Criteriaand 
Section 4.2, Exclusio n Cri teria.
Eligibilit y forstudy  vaccinat ion is determined by following the criteria outlined in 
Section 4.3, Cri teria for Del ay of Vaccination .
Study  vaccines should not be administered to individuals wit h known hypersensit ivity to 
any co mponent of the vaccines.
Standard immunizat ion practices are to be observed and car e shoul d be taken to 
administer the inject ion intramuscularl y. Bef ore administering vaccine, the vaccinat ion 
site is to be di sinfec ted wi th a skin disinfectant ( e.g., 70% alcoho l). Allow the skin to dry . 
DO NOT inject intravascularly or intragluteally .
Aswith all injectable vaccines, trained medical personnel and appropriate medical 
treatm ent shoul d be readily  available in case of anaphylact ic react ions following vaccine 
administration. For example, epinephrine 1:1000, diphenhydramine, and/or other 
medica tions f or treating anaphylaxis should be available.
6.4 Vaccine Administration Error or Overdose of Vaccine
Vaccine administration error is defined as receiving a dose of study  vaccine that was not 
reconstituted as instructed or administered by a differen t route from the intended route of 
administration. An overdose of study  vaccine (whether accidental or intent ional) is 
defined when a dosage higher than the recommended dosage is administer ed in one dose Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 60of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015of study  vaccine .An administration error includes underdosing, where an incomplete 
dose of vaccine is given, caused by mechanical failure or other reason. 
An overdose would also occur if two doses of the study  vaccine are administered within 
half the t ime of the recommended interval between doses, as defi ned in the protocol.
Any vaccine administration error or overdose of study  vaccine detailed in this protocol 
must be reported as an adverse event, and if the vaccine administration error or overdose 
is associated with a serious adverse event, it must be re ported as such within 24 hours to 
the Sponsor or del egate .
6.5 Prior and Concomitant Medications and Vaccines
All influenza vaccinat ion history  in the 5 y ears prior to subject enrol lment into the study  
is to be obtained fro m the subject and recorded in th e subject’s source records. All 
influenza vaccinat ions received by  the subject in the 12 months prior to enrol lment (or for 
the 2016 –2017 flu season) into the study  shoul d addi tionally  be recorded on the Pri or 
and Conco mitant Medi cations CRF .
All medicat ionsand vaccines taken or received by the subject within 2 months pri or to the 
start of the study  are to be recorded on the Prior and Concomit ant Medi cations CRF. Any 
blood products received wit hin 3 months prior to enro llment m ust al so be documented in 
the Prior and Concomitant Medicat ions CRF . Vitamins and minerals are excluded from 
this scope .
The use of antipyret ics and/or analgesic medicat ions wit hin 24 hours prior to vaccinat ion 
must be ident ified and the reason for their use (prophylaxis versus trea tment) m ust be 
described in the source document and Conco mitant Medi cations CRF. The use of 
antipyretics/analgesics within 24 hours prior to vaccine administration is a reason to delay 
study  vaccinat ion (see Section 4.3, Cri teria for Delay  of Vaccinat ion).The use of low-
dose aspi rin for cardi ovascular prophylaxis is not considered effective analgesic therapy 
and is thus allowed. 
Medicat ions taken for prophylaxis are those intended to prevent the onset of symptoms. 
Medicat ions taken for treatment are intended to reduce or eliminate the presence of 
symptoms that are present.
Concomitant medicat ions include all medicat ions (including vaccines) taken 
by/administered to the subject at and after enrol lment .
Administrati on of any other influenza vaccine, seasonal or pandemic, is prohibited unt il 
after collect ion of the fo llow-up serol ogy on Day  22.
The fo llowing concomitant medicat ions will be recorded in the Conco mitant Medi cations 
CRF:Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 61of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015All conco mitant m edicat ions from  Day 1 to Day  22
All medications associated with SAEs, NOCD, AESIs, and AEs that lead to premature 
withdrawal  from the study , from Day 1 to study  terminat ion
All vaccines, including any  seasonal  or pandemic influenza vaccines, fro m Day 1 to 
Day 181
When recordin g concomi tant medicat ions/vaccines, they  shoul d be checked against the 
study  entry  and cont inuat ion criteria in Section 4, Select ion of Study  Popul ationto ensure 
that the subject should be enrolled/continue in the study .
Use of the following conco mitant medicat ions after enrol lment and prior to the Day 22 
blood collection shoul d be docum ented on the Concomitant Medicat ion CRF page as they  
may have an effect on the interpretation of the study object ives and therefore may b e 
determined to be a reason for exclusion fro m one of the analysis sets.
Anti-viral medicat ion following ILI, pri or to obtaining a NP swab
Blood, bl ood products or a parenteral immunoglobulin preparat ion
Oral or sy stemic corti costeroi ds (topi cal, inhaled, intranasal corticosteroids are
permitted)
Other immunosuppressive agentsDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 62of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20156.6 Vaccine Supply, Labeling, Storage and Tracking
The Sponsor will ensure the fo llowing:
Supply  the study  vaccines
Appropriate la beling of all study vaccines provi ded that com plies with the l egal 
requi rements of each country  whe re the study  is to be perform ed
The I nvestigator must ensure the fo llowing:
Acknowledge receipt of the study  vaccines by  a desi gnated staff member at the site, 
including:
oConfirmation that the vaccines were re ceived in good condition
oConfirmation to the Sponsor of the temperature range during sh ipment fro m the 
Sponsor to the I nvestigator’s designated storage location
oConfirmation by  the Sponsor that the vaccines are authorized for use
Proper storage of the study vaccines, including:
oStorage in a secure, locked, temperature -controlled locat ion
oProper storage according to the instr uctions specified on the labels
oAppropriate record keeping and inventory  of the study  vaccines, including regular 
docum entati on of  adequate storage tem perature
Appropriate use of the study  vaccines, including:
oNo use of vaccines prior to receipt of authori zation for use fro m the Sponsor
oUse only in accord ance with the approved protocol
oProper handling, including confirmat ion that the vacc ine has not expired prior to 
administration
oAppropriate docum entati on of  administrati on of  vaccines to study  subjects 
including:
▪Date, dosage, batch/lot numbers, expiration dates, unique identifying numbers 
assigned to subjects and study  vaccines, and t imeof vaccine administration. 
This information will be maintained in an accountabilit y log that will  be 
reviewed by  the si te monitor
▪Reconciliat ion of all vaccines received from the Sponsor. Reconciliat ion is 
defined as maintaining records of which and how m any vaccines were 
received, which vaccines were administered to subjects, which vaccines were 
destroy ed at the si te, and which vaccines were returne d to the Sponsor, as 
applicableDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 63of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Proper adherence to the local inst itutional po licy wit h respect to de struction of  study  
vaccines
Com plete record keeping of vaccine use, wastage, return or destruction, including 
docum entati on of :
oCopy  of the si te’s procedure for de struction of hazardous material
oNumber of doses destroy ed, date of destructi on, destructi on code (if available), 
method of destruction, and name of in dividual performing destruction
Vaccines that have been stored different ly from the m anufacturer’s indicat ions must not
be used unless the Sponsor provides written authorizat ion for use. In the event that t he use 
cannot be authorized, the Sponsor will make every effort to replace the vaccine supply. 
All vaccines used in conjunct ion with this protocol must be stored separately from normal 
hospi tal/pract ice stocks to prevent unintent ional use of study  vaccines outsi de of  the 
clinical study  setting.
Moni toring of vaccine accountabilit y will be perf ormed by the study  monitor duri ng site 
visits and at the complet ion of the study .
At the conclusio n of the study , and as appropriate during the course of the study , the 
investigator must ensure that all unused study  vaccines, packaging and supplementary  
labels are destroy ed locally  (upon approval  from Sponsor) or returned to the Sponsor.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 64of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20157. ASSESSMENTS
7.1 Safety Assessment
The m easures of safet y used in this study  areroutine clinical procedures. They  include a 
close vigilance for, and stringent reporting of, selected local and systemic adverse events 
routi nely mo nitored in vaccine clinical studies as indicators of reactogenicit y.
An adverse event (AE) is defined as an
y untoward medical occurrence in a subject or 
clinical invest igation subject administered a pharmaceutical product at any  dose that does 
not necessarily have to have a causal relat ionship wi th this treatm ent. Therefore, an AE 
can be any  unfavorable and uni ntended sign (including an abnormal laboratory  finding, 
for example), symptom, or disease temporally associated with the use of an 
investigat ional product, whether or not considered related to the invest igational product. 
This definit ion includes intercurr ent illnesses or injuries and exacerbat ion of pre -exist ing 
condi tions.
The peri od of  observat ion for AEs extends fro m the time the subject signs informed 
consent until he or she completes the specified safety  follow-up peri od or terminates the 
study  early  (whichever com es first). AEs occurring after the informed consent form is 
signed but pri or to receiving study  vaccine/product will be documented as an adverse 
event and recorded within source document. However, any AEs occurring prior to receipt 
of any stu dy vaccine will be listed separately fro m “treatm ent em ergent” AEs (AEs 
occurring after administration of the first study  vaccine).
Adverse events are collected as either so licited or unso licited adverse events. Solicited 
events are derived from organized data collection systems, such as Subject Diaries or 
interview.
7.1.1 Solicited Adverse Events
The term  “reactogeni city” refers to solicited signs and symptoms (“so licited adverse 
events”) occurring in the hours and days fo llowing a vaccinat ion, to be coll ected by  the 
subject or legal representative (s) for 7 consecut ive days, using a pre defined Diary Card .
The fo llowing solicit ed adverse eve nts are included in the Diary Card . Each adverse event 
is to be assessed using the scoring system reported in parenthe ses below: Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 65of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Solicited Local Adverse Events
Induration, ery thema and ecchymosis will be measured by  the subject and r ecorded 
directly on the DiaryCard .
Inject ion site pain will be measured as fo llows: grade 0= absent, grade 1/mild= present 
but does not int erfere wit h activit y, grade 2/m oderate = interferes wit h activit y, grade 
3/severe = prevents daily  activity.
Solicited Systemic Adverse Events
Loss of appetite will be measured as fo llows: grade 0 = none, grade 1/mild = eating less 
than usual with no effec t on norm al activi ty, grade 2/m oderate = eating less than usual / 
interfered wi th norm al activi ty, grade 3/severe = not eating at all.
Nausea will be measured as fo llows: grade 0 = none, grade 1/mild = no interference with 
daily  activi ty, grade 2/m oderate = interferes with daily act ivity, grade 3/severe = prevents 
daily  activi ty.
Fatigue, generalized myalgia, generalized arthralgia, headache and chills will be 
measured using the fo llowing scoring system: grade 0 = none, grade 1/mild= no 
interference wi th daily act ivity, grade 2/m oderate = interferes wit h daily act ivity, grade 
3/severe = prevents daily  activity.
Vomit ing will be measured as fo llows: grade 0 = none, grade 1/mild = 1 -2 times per 24 
hours, grade 2/moderate = 3 to 5 times per 24 hours, grade 3/se vere = 6 or more times in 
24 hours or requires intravenous hy dration.
Diarrhea will be measured as fo llows: grade 0 = fewer than 2 loose stools per 24 hours, 
grade 1/mild = 2 -3 loose stool s in 24 hours, grade 2/moderate = 4 -5 stools in 24 hours, 
grade 3/se vere = 6 or more loose stools in 24 hours or requires intravenous hydration.
Other Solicited Adverse Events
Use of analgesics/ant ipyretics will be captured as “absent” or “present” and will also 
be summarized by “for treatment” or “for prophylaxis”;
Body  temperature will be captured. Fever is defined as body  temperature 
≥38.0°C /100.4°F , as measured preferably  orally.
The study  staff must review th e data entered i nto the Diary  Card as described in Section 
3.4.2, Tool s Used for Data Collect ionand Section 5.3.1, Follow -up Clinic Visit(s) .
Note: Any  solici ted adverse event that meets any  of the f ollowing cri teria must be entered 
into subjects’ source document (see Section 9.1, Source Documentation ) and also as an 
adverse event on the Adverse Event CRF:
Solicited local or systemic adver se event that continues bey ond Day 7after 
vaccinationDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 66of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Solicited local or systemic adverse event that le ads to a visi t to a heal thcare provi der 
(medically  attended adverse event, see Section 7.1.3, Evaluat ion of Adverse Events )
Solicited local or systemic adverse event leading to the subject withdrawing fro m the 
study  or the subject being withdrawn from the study  by the invest igator (adverse event 
leading to withdrawal, see Section 7.1.3, Eval uation of Adverse Events )
Solicited local or systemic adverse event that otherwise meets th e definit ion of a 
serious adverse event (see Section 7.1.4, Serious Adverse Events )
7.1.2 Unsolicited Adverse Events
An unso licited adverse event is an adverse event that w as not solicited using a Diary  Card 
and t hat was spontaneously co mmunicated by a subject or legal representative (s) who has 
signed the informed consent.
All unso licited adverse events, and medicat ions used to treat them, will be collected from 
study  admissi on (at the time of informed consent) thr ough the Day  22 clinic visit. After 
the day  22 visit, only  unsolici ted adverse events, and medicat ion used to treat them, which 
meet criteria for the fo llowing will be co llected: serious adverse events, adverse events of 
special interest, new onset of chro nic disease, and events leading to study  discontinuati on. 
7.1.3 Evaluation of Adverse Events
Every  effort shoul d be made by  the I nvest igator to evaluate safety informat ion reported 
by a subject for an underlying diagnosis and to capture this diagnosis as the event in the 
AE page. In other words, the practic e of reporting only  symptom s (e.g., “cough” or “ear 
pain”) are better reported accor ding to the underlying cause ( e.g., “asthma exacerbation” 
or “oti tis media”).
The severit y of events reported on the A dverse Events CRF will be determined by the 
Invest igator as:
Mild: transi ent wi thno limitat ion in normal daily act ivity.
Moderate: some limitation in normal daily act ivity.
Severe: unable to perform normal daily  activi ty.
The rel ationship of the study  treatment to an AE will be determined by the I nvestigator 
based on the fo llowing definit ions:
1. Not Related
The AE is not related to an investigational vaccine if there is evidence that clearly 
indicates an alternat ive explanat ion. If the subject has not rec eived the vaccine, the timing 
of the exposure to the vaccine and the onset of the AE are not reasonably  related in t ime, Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 67of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015or other facts, evidence or arguments exist that reasonably suggest an alternat ive 
explanat ion, then the AE is not related.
2.Possibly Related
The administration of the invest igational vaccine and AE are considered reasonably 
related in t ime and the AE could be explained by exposure to the invest igational vaccine 
or by  other causes.
3. Probably  Related
Exposure to the invest igational vaccine and AE are reasonably related in time and no 
alternat ive explanat ion has been ident ified.
The rel ationship of the study  treatm ent to an unso licite d AE will be determined by the 
Invest igator . 
Note: solicited AEs will not be evaluated for relat ionship to study  treatm ent. Grading for 
severit y of solici ted local and systemic AEs is described in Section 7.1.1, Solicited 
Adverse Events .
Adverse events will also be evaluated by  the Investi gator for the co existence of an y ofthe 
other fo llowing condi tions:
AESI see Section 7.1.4.1, AESI
“New onset of chronic disease” (NOCD): an adverse event that isa new diagnosis of a 
chronic medical condit ion that was not present or suspecte dprior to study  enro llment
AEs leading to withdrawal: adverse events leading to study withdrawal
If solicited or unsolicited adverse events have been reported and the subject or legal 
representative (s) indicated that the symptoms required medical attendan ce or were of 
concern, the subject or legal representative (s) must be contacted for further informat ion.
When the subject or legal representati ve(s) is contacted for any  of these reasons, the 
contact m ust be docum ented in the subject’s source documentation .
All AEs, regardless of severit y, will be monitored unt il resolution or until the I nvest igator 
assesses them as chronic or stable. All subjects experiencing AEs -whether considered 
associ ated wi th the use of the study  vaccine or not -must be monitored u ntil symptoms 
subside and any abnormal laboratory  values have returned to baseline, or until there is a 
satisfactory  explanat ion for the changes observed, or until death, in which case a full 
pathol ogist’s report should be supplied, if possible. The I nvest igator’s ass essment of 
ongoing AE s at the time of each subject’s last visit  shoul d be docum ented in the subject’s 
medical chart.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 68of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20157.1.4 Serious Adverse Events
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any  
dose resul ts in one or m ore of  the fo llowing:
Death
Is life-threatening (i .e.the subj ect was, in the opinion of the I nvest igator, at immediate 
risk of death fro m the event as it occurred); it does not refer to an event which 
hypotheti cally  might have caused death i f it were m ore severe
Requi red or prol onged hospitalization
Persi stent or si gnificant disabilit y/incapacit y (ie, the event causes a substant ial 
disrupt ion of a person’s abilit y toconduct normal life funct ions)
Congenital anom aly/or bi rth defect
An importa nt and significant medical event that may  not be immediately  life 
threatening or resulting in death or hospitalizat ion but, based upon appropriate 
medical judgment, may  jeopardi ze the subject or may require intervent ion to prevent 
one of the other outcomes listed above
Adverse events which do not fall into these categories are defined as non -serious.
It should be noted that a severe adverse event need not be serious in nature and that a 
serious adverse event need not, by  defini tion, be severe.
AllSAEs will be evaluated by  the I nvest igator for relat ionship of the event to study  
vaccine. SAEs that are judged to be possibly or probably related to the study  vaccine 
shoul d be reported  as related/suspected events.   
The rel ationship of the study  treatm ent to an SAE will be determined by the I nvestigator 
based on the fo llowing definit ions:
1. Related/suspected
The SAE is judged by the I nvest igator to be possibly or probably related to the study  
vaccine on the AE CRF page (see Section 7.1.3, Evaluat ion of Adverse Events ).
2. Not Related
The SAE is not related if exposure to the study  vaccine has not occurred, or the 
occurrence of the SAE is not reasonably related in time, orthe SAE i s consi dered 
unlikely  to be rel ated to use of the study  vaccine, i .e. there are no facts (evidence) or 
argum ents to suggest a causal relationship.
The rel ationship of the study  vaccine to an SAE will be d etermined by the I nvestigator .
SAEs will be evaluated by  Seqirus oritsdesignee for “expectednes s.” An unexpected AE 
is one that is not listed in the current Summary  of Product Characteristics or the Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 69of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Invest igator’s Brochure or an event that is by nature more specific or more severe than a 
listed event.
Any pre-exist ing event or condit ion that results in hospi talizati on shoul d be recorded on 
the Medi cal History  CRF. If the onset of an event occurred before the subject entered the 
study (eg, any  pre-planned hospi talizat ion for condit ions like cosmet ic treatments or for 
non-emergency  routine visi ts for apre-exist ing condit ion), the hospitalizat ion woul d not 
lead to an AE being classified as seri ous unless, in the view of the I nvest igator, 
hospi talizati on was prol onged as a result of participation in the clinical study  or was 
necessary  due to a worsening of the pre -exist ing condit ion.
7.1.5Adverse Events of Special Interest
The Investigator will be provided wit h a list of AESIs prior to FSFV. Receipt of this list 
will be documented and stored, along with the list of AESIs in the Invest igator Study  File. 
During the course of the trial the list of AESIs may change. If this occurs the investigators 
will be advised of the change and confirmat ion of receipt will be documented. The 
updated list of AESIs and documentation of receipt are also stored in the Invest igator 
Study  File.
Subjects will be assessed at each visit for any  new medical events or signs or symptoms 
that coul d possibly  indicate an AESI. The subject will be asked whether any  new 
diagnosis has been given to the subject through a review o f recent me dical  history . Shoul d 
a qualified healt h care practit ioner who i s not the Investigator suspect a potential AESI, 
she/he shoul d prom ptly inform the Invest igator. The AESI diagnosis will be recorded in 
the medical chart/source document as well as in EDC along with any medicat ion used to 
treat the condit ion.
Onset of an AESI is to be reported to Seqirus or its designee via EDC in the same manner 
and time frame as an SAE (seeSecti on 7.1.6 and SAE/AESI Reporting Plan ). 
All AESIs will be reviewed for signal evaluat ion by Seqirus or its desi gnee and as sessed 
for expedited reporting.
7.1.6 Methods for Recording and Reporting Adverse Events and Serious Adverse 
Events
Findings regarding adverse e vents m ust be reported on an Adverse Events CRF, as 
specified in Section 7.1.1, Solici ted Adverse Events . All findings in subjects experiencing 
AEs must also be reported in the subject's source document.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 70of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015All SAEs and AESIs which occur duri ng the course of the study , whether considered to 
be associ ated wi th the study  vaccinat ion or not, must be reported within 24 hours of the 
site becoming aware of the event to Seqirusor its desi gnee via EDC . If entry  into EDC
is not possible (eg, because t he system is non -functio nal), the paper SAE/ AESI Form  
must be completed and submitted via facsimile/email to Seqirus or its designee. Refer to 
SAE/AESI Reporting Plan for s pecific instructions and contact details for collect ing and 
reporting SAEs .
Any medi cation or other therapeutic measures used to treat the AE will be recorded on the 
appropriate CRF(s) in addit ion to the outcome of the AE.
After receipt of the init ial report ing, representatives of Seqirusorits designee will contact 
the Invest igator if i t is necessary  to obtain further informat ion for assessment of the event.
All SAEs must be reported by  the I nvestigator to his/her corresponding EC /IRB or   
applicable regulatory  authori ties in accordance wi th institutional po licy/regulatory 
requi rements ,and adequate documentation of this notification must be provided to the 
Sponsor.
Seqirusor its desi gnee must al so com ply wit h the applicable regulatory  requi rement(s) 
related to the reporting of suspected unexpected serious adverse vaccine react ions (als o 
known as SUSARs) to the regulatory  authori ty(ies) and the IRB/EC. If a SUSAR or other 
safet y signal relating to use of one of the study  vaccines is reported to Seqirus or its 
designee, the Sponsor will co mmunicate the informat ion to the I nvestigat or and the 
Invest igator will be responsible for sub mitting this informat ion to the EC/IRB and other 
relevant authori ties.
7.1.6 .1 Post-Study Events
Any SAE that occurs outside o f the protocol -specified fo llow-up peri od and considered to 
be caused by the study  vaccine m ust be reported to Seqirus or its desi gnee. There i s no 
time limit on reporting for SAEs related to study  vaccine. Instructions and contact details 
for collect ing and reporting these suspected SAEs will be provided to the I nvest igator.
7.1.7 Pregn ancies
Not applicable for this study .
7.1.8 Safety Laboratory Measurements
No scheduled safet y laboratory  measurem ents are pl anned for this study .Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 71of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20157.2 Efficacy Assessment
Not applicable.
7.3 Immunogenicity Assessment
The m easure of immunogenicit y use d in this study , hem agglut ination inhibit ion (HI) i s 
widely accepted and generally  recognized as reliable, accurate, and relevant (able to 
describe the qualit y and extent of the immune response).
The immunogenicit y analyses will evaluate immunogenicit y of aQI V and the co mparator 
aTIVs measured by the HI assay by  titrating ant ibodies against homo logous or 
heterol ogous influenza strains. Homolo gous strains are antigenically  similar to the strains 
in the vaccine and heterologo us are antigenically dist inct ( CDC , 2014 ).
Addit ional immuno logic assays, including microneutralizat ion, may be used to m easure 
neutralizing ant ibodies. 
Testing will be conducted by Seqirus designated qualified laboratory  personnel blinded to 
the treatment assignment and the visit. Please see the Protocol Ancillary Document for 
name(s) and details.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 72of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20158. STATISTICAL CONSIDERATIONS
8.1 Endpoints
8.1.1     Primary Endpoints
8.1.1 .1 Co-Primary Immunogenicity Endpoint s
The immunogenicit y of study  vaccines will be assessed 21 (i.e., on Day  22) days after 
vaccine administration by measuring the hemagglutinat ion inhibit ion (HI) antibody  titers 
to the four virus strains included in the vaccines.
The noninferiorit y of aQIV com pared to aTIV -1, and to aTIV -2 will be assessed for t he 
eight co-primary endpo ints of HI geom etric mean titer (GMT) and seroconversio n rate 
(SCR) for each virus strain included in the vaccines as fo llows:
The G MT rati o* for the A/H1N1 strain
The GMT rati o for the A/H3N2 strain
The GMT rati o for the B strain (Yamagata lineage)
The GMT rati o for the B strain (Victoria lineage)
The difference between the SCR**for the A/H1N1 strain
The difference betwee n the SCR for the A/H3N2 strain
The difference between the SCR for the B strain (Yamagata lineage)
The differenc e between the SCR for the B strain (Victoria lineage)
Immunogenicit y resul ts obtained from  aTIV -1 and aTIV -2 for both A/H1N1 and A/H3N2 
strains
will be pooled for comparison with aQIV.
*The GMT ratio is de fined as the geometric mean of the post-vaccinatio n (Day 22) HI 
titer for aTIV-1 (or aTIV -
2)over the geometric mean of postvaccination (Day 22) HI titer 
for aQIV.
**The SCR is defined as the percentage of subjects w ith either a prevaccination HI titer 
< 1:10 and a post -vaccination HI titer ≥ 1: 40 or a p
revaccination HI titer ≥ 1:10 and a ≥ 
4-fold increase in postvaccination HI titer.
The second co -primary immunogenicit y objective for aQIV will be assessed 21 day s after 
vaccine administration by applying CBER criteria for the el derly popul ation for each of 
the
4 strains included in aQIV :
The percent of subjects achieving seroconversio n for HI antibodyDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 73of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015The percent of subjects achieving an HI antibody  titer ≥ 1:40
The study  is consi dered successful  if the (16) co -primary endpo ints are achieved.
8.1.2 Seco ndary Immunogenicity Endpoint s
The m easures of immunogenicit y of aQIV, aTIV -1 and aTIV -2 used for 
Secondary  object ive 1 as determined by the HI assay against ho molo gous strains 
at Day  1 and 22 (unless indicated otherwise), include the following:
GMT: Geom etric mean of HI titers on Day  1 and Day  22
Geom etric mean rati o (GMR)*: The geom etric m ean of the fo ld increase of 
post-vaccinat ion HI ti ter over the pre -vaccination HI titer (Day  22/Day  1)
The percentage of subjects with a titer ≥40 at Day  1 and Day 22
SCR: the percentage of subjects with either a prevaccination HI titer < 1:10 
and a postvaccinat ion HI ti ter ≥ 1:40 or a prevaccinat ion titer ≥ 1:10 and a ≥ 4 -
fold increase in postvaccination t iteron Day  22
For Secondary  objective 2 ,the immuno logic superi ority of HI ant ibody  responses 
forthe alternate B strain (the influenza B strain included in the aQIV but not in the 
aTIV formulat ion) in aQIV will be assessed for each aTIV separately, usingthe
endpo ints of the rati o of HI GMT and the difference of SCR for each B virus 
strain 21 days after vaccinat ion.
8.1.3 Secondary Safety Endpoints
Safety and tol erabilit y will  be assessed by  the f requency and severit y of:
Solicited local and systemic a dverse events (AEs) for 7 days fo llowing 
vaccinati on (Day  1 through Day  7)
All unso licited AEs for 21 days fo llowing vaccinatio n (Day  1 through Day  22) 
and medicat ion associated with these events
Serious AEs (SAEs), AEs leading to withdrawal from the study , new onset of 
chronic diseases (NOCDs), AEs of special interest (AESIs), and concomitant 
medicat ions associated with these events as collected fro m Day 1 through Day  
181Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 74of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20158.1.4Exploratory Immunogenicity Endpoint s
Exploratory  immunogenicit y endpo ints incl ude:
GMTs: Geometric mean HI titers (GMTs) at Day  1 and Day  22
SCRs: Percentage of subjects with either a prevaccinat ion HI titer < 1:10 and a 
postvaccinat ion HI titer ≥ 1:40, or a prevaccination titer ≥ 1:10 and a ≥ 4- fold 
increase in postvaccination t iterat Day  22.
In case of any addit ional optional immunogenici ty analyses, such as MN, or 
assessments using heterologous influenza strains, the immune response will be 
characterized in a similar manner as described in the secondary  immunogenici ty 
endpo ints section above.
Further details regarding the endpo ints and analyses of these assays will be described in 
the Statistical Analysis Plan (SAP) prior to unblinding.
8.2 Success Criteria
The study  is consi dered successful  if the co -primary objectives are achi eved .
8.2.1 Success Criteria for Co-Primary Endpoints
8.2.1.1 To demonstrate noninferiority
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance for 
Industry  Clinical  Data Needed to Support Licensure of Seasonal Inact ivated I nfluenza 
Vaccines 2007), aQIV will be considered to be noninferior to aTIV-1 , containing the 
same virus strains as the US licensed adjuvanted trivalent influenza vaccine, and aTIV -2, 
containing the alternate B strain if, for each of the four strains, the f ollowing statistical 
criteria are met:
The upper bound of the two -sided95% confidence interval (CI) for the rati o of the 
GMTs does not exceed 1.5. The
GMT ratio will be calculated as GMT aTIV/GMT 
aQIV; and
The upper bound of the two -sided 95% CI for the difference between the SCRs 
does not exceed 10%. The differen ce in SCRs will be calculated as
Seroconversio n aTIV–Seroconversio n aQIVDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 75of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20158.2.1.2 CBER criteria for Co- Primary E ndpoints:
The endpo ints for percent of subjects vaccinated with aQIV achieving seroc onversio n and 
HI titer ≥ 1:40 at Day 22 will be assessed against the criteria described in CBER 
Guidance Clinical Data Needed to Support the Licensure of Seasonal Inact ivated 
Influenza Vaccines ( FDA, 2007):
The l ower bound of t he two -sided 95% confidence interva lfor the percentage of 
subjects achieving seroconversio n for HI ant ibody  shoul d meet or exceed 30%
The l ower bound of the two
-sided 95% confidence interval for the percentage of 
subjects achieving an HI antibody  titer ≥ 1:40 should meet or exceed 60%
The stati stical evaluat ion consists of the observed proportion together with the 
correspondi ng two -sided 95% CI per strain. No adjustment for type I error for mult iplicity 
is made.
No adj ustment for type I error for m ultiplicity will bemade. The study  is successful if the 
co-primary immunogenicit y object ives are achieved.
8.2.2       Success C riteria for Secondary Objective s
8.2.2.1 Success Criteria for Secondary Immunogenicity Endpoints
There are no specific success criter ia for the assessment of immunoassay  resul ts(first 
secondary
 object ive).
Superi ority of aQIV versus aTIV -1 and aTIV -2 for the alternate B strain will be assessed 
using the GMT ratio ( GMT aTIV/GMT aQIV) and difference in SCR ( SCR aTIV–SCR aQIV) at 
Day 22. P oint estimates and two -sided 95% CIs will be obtained as described for the 
primary endpoint. Superi ority will be declared if the upper limit of the two- sided 95 % CI 
for the difference in SCR aTIV–SCR aQIV) is < 0%, and the upper limit of the two -sided 
95% CI for the GMT ratio (GMT aTIV / GMT aQIV) is <1 for both B strains.
8.3 Description of Analysis Sets
There will be four analysis populat ions defined for the study  analyses. These are defined 
in more detail  in the SAP.
8.3.1 All Enrolled Set
All screened subjects who provide informed consent, receive subject ID, and provide
demographic a nd/or baseline screening informat ion, regardl ess of the subject’s 
rando mizat ion and treatment status in the study .Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 76of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20158.3.2 Full Analysis Set
All subjects in the All Enrolled Set who are randomized and receive a study  vaccinat ion. 
The FAS will be used to produce summaries and listings of subject characterist ics.
8.3.3Safety Set
The Safet y Setwill co mprise all subjects in the FAS who received at least one dose or 
partial dose of Study  Vaccine and have provided any  evaluable fo llow-up safet y data. The 
safet y set will be used to produce summaries and listings of all safet y data.
8.3.4Evaluable Set –Immunogenicity Analysis
The Evaluable Setfor immunogenicit y analyses will comprise all  subjects in the FAS 
who:
receive vaccine on Day 1
provi deserol ogy specimens which yield valid serology assay result s from both Day 1 
and Day 22
donot experience a laboratory -confirmed influenza illness between Day 1 and Day 
22, and
donot rec eive any prohibited medication during the study that is medically assessed 
to potentially impact immunogenicit y resul ts
8.3.5Per-Protocol Set
The Per -Protocol Set(PPS) will co mprise all subjects in the Evaluable Set who do not 
have a ny protocol deviat ions that are medically assessed as potentially impact ing on 
immunogenicit y resul ts.  
The Per Protocol Set will be the primary  popul ation of interest for the primary /secondary  
immunogenicit y analysis and a supporting analysis will be performed using the Ev aluable 
Set
.Membership of the PPS will be determined prior to unblinding the study .
Duplicate tables o f primary  and secondary  immunogeni city analyses m ay also be
produced based on the Evaluable populat ion if there is > 1% difference in the total number 
ofsubjects between the Per -Protocol Populat ion and the Evaluable Populat ion. The 
decisio n to produce tables based on the Evaluable Populat ion will be made by Seqirus 
after popul ation sets are finalised and prior to unblinding.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 77of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Examples for subjects exclude d due to other reasons than protocol deviat ions are subjects 
who wi thdrew inform ed consent.
In case of misrando mizat ion with regard to treatm ent arm , the subject i s excluded fro m 
the PPS .
If a subject is unblinded during the study , except for SUSAR, he/she will be excluded 
from the PPS.
8.3.6Subgroups
The i mmunogenicit y analysis at Day  22 will  be perform ed by  stratifying for the following 
subgroups:
Age at enrol lment ( ≥65-74, ≥75-84, and ≥85 y ears)
Sex
Race
Previous influenza vaccinati on in the past 5 ye ars (yes/no)
Com orbidi ty/risk (yes/no, defined as assessment score < 50 or ≥50 based on scale 
described in Section 5.1.2 ) (Hak, 2004 )
Safety analysis of any unso licited adverse events and of an y local, any  systemic, or any  
other solicited adverse events (all adverse events combined for each s uch category ) will 
be perform edby stratifying for the fo llowing subgroups : 
Age at enrol lment (≥65-74, ≥75-84, and ≥85y ears)
Sex
Race
8.3.7Protocol Devi ations
A protocol deviat ion is any change, divergence, or departure from the study  design or 
procedures of a study  protocol . A protocol  deviat ion may be a reason to remove data from 
an analysis set at the time of analysis. Majorprotocol deviat ions will be defined as 
exclusio nary from the analysis according to protocol objectives and endpo ints, which will 
be specified in the statist ical analysis plan. In some cases ,exclusio n of data may be due to 
a reason oth er than a protocol deviat ion, e.g.early termina tion.
Any deviat ion that affects the subject's rights, safety, or well -being and/or the
completeness, accuracy  and reliabilit y of the study data const itutes amajo rprotocol
deviat ion. Changes or alterations in the conduct of the trial which do not have a majorDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 78of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015impact on the subject's rights, safety  or well -being, or the completeness, accuracy  and
reliabilit y of the study  data are not considered majorprotocol deviat ions. All deviat ions 
will be reviewed to determine the final list of deviations that will b e used for exclusio n 
from the analysis set(s). This will be defined in the statist ical analysis plan prior to 
unblinding.
All protocol deviat ions will be classified into those which are majo rand those which are 
not.  Majorprotocol deviat ionswill be summ arized by  vaccine, center (overall) and 
grouped into the different categories as defined above. The site monitor will keep the 
investigator informed of all protocol  deviat ions, so that the invest igator can comply wit h 
reporting these deviat ions to the loca l EC/IRB according to their inst itutional po licy.
Prior to unblinding, designated staff at the Sponsor will develop a memo that describes
the selected deviat ions that are ident ified as exclusio ns from analysis populat ions. This
memo will be included in the trial master file.
8.4 Statistical Analysis Plan
A co mplete description o f the stati stical analyses and methods will be available in the 
Statistical Analysis Plan (SAP), which will be finalized prior to unblinding .
8.4.1 Analysis of Demographic and Base line Characteristics
Descript ive statistics (mean, standard deviation, m edian, minimum  and maximum ) for
age, height, weight, BMI, and com orbidity score at enro llment will be calculat ed overall 
and by  vaccine group s.
Distribut ions of subjects by sex, ethnic origin (race, ethnicit y), and previous vac cinat ion 
status will be summarized overall, and by vaccine group.
8.4.1.1 Concomitant Medications
Use of conco mitant medication will be presented by treatment, age cohort, therapeutic 
area,and preferred drug nam e.
Concomitant medications are all medicat ions taken during the study  period, including 
those started before but ongoing at vaccinat ion.
If astart date for a m edicat ion is partially or f ully missing, and it is unclear as to whether 
the medicat ion is prior or concomitant, it will be assumed that it is conco mitant.
Medicat ions will be coded us ing the WHO Drug dictionary .Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 79of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20158.4.2 Analysis of Primary Objective(s)
8.4.2.1 Analysis of Primary Efficacy Objective(s)
Not Applicable.
8.4.2.2 Analysis of Co- Primary I mmunogenicity Objective s
The c o-primary immunogenicit y object ives are:
1.To dem onstrate that vaccinat ion with aQIV elicit s an immune response that is 
not inferior to that of an aTIV con taining the same virus strains as the US 
licensed adjuvanted influenza va ccine (Fluad, aTIV -1), and an aTIV containing 
the alternate B strain (aTIV -2) am ong adul ts ≥65 years of age
2.To assess the immunogenicit y of aQIV in adults 
≥65 years of age, based on 
CBER (Center for Bio logics Evaluati on and Research) criteria
8.4.2.2.1 Statistical Hypotheses
Noninferiority of aQIV to aTIV -1 and aTIV -
2
To dem onstr ate that vaccinat ion with aQIV elicit s an immune response that is not inferior 
to that of an aTIV containing the same virus strains as the US licensed adjuvanted 
influenza vaccine (Fluad, aTIV -1), and an aTIV containing the alternate B strain (aTIV -2) 
among adul ts ≥65 years of age. according to the FDA Guidance on seasonal inact ivated 
influenza vaccines (Guidance for Industry Clinical Data Needed to Support Licensure of 
Seasonal Inactivated Influenza Vaccines 2007) . 
aQIV will be considered to be noninferio r to aTIV if, for each of the four strains, the 
following statistical criteria are met: 
The upper bound of the two -sided 95% CI forthe rati o of the GMTs does not 
exceed 1.5. The GMT ratio will be calculated by GMT aTIV/GMT aQIV
The upper bound of the two -sided 95% CI for the difference between the SCRs 
does not exceed 10%. The difference in SCR will be calcul ated by SCR aTIV–
SCR aQIV
In mathemat ical notation, the stati stical hypotheses to be tested for the primary  
immunogenicit y analysis correspond to: 
H0: GMTri > 1.5, for any strain 
Ha: GMTri≤ 1.5, for all strain 
and Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 80of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015H0: Di> 10, for any strain 
Ha: Di≤ 10, for all strain 
where GMTriis any of the 4 strain -specific post immunogenicit y dose GMT rati os 
namely,
GMT aTIV -1/GMT aQIVfor B/Yam agata strain 
GMT aTIV -2/GMT aQIVfor B/Vi ctoria strain 
Pooled GMT( aTIV -1and aTIV -2)/GMT aQIVfor A/H1N1 strain 
Pooled GMT( aTIV -1and aTIV -2)/GMT aQIVfor A/H3N2 strain 
and Di is the 4 strain -specific post dose SCR s (π aTIV -1, πaTIV -2, πaQIV) difference, namely ,
πaTIV-1– π aQIVfor B/Yamagata strain 
πaTIV -2– π aQIVfor B/Victoria strain 
Pooled π (aTIV -1 and aTIV -2)-πaQIVfor A/H1N1 strain 
Pooled π (aTIV -1 and aTIV -2)-πaQIV for A/H3N2 strain 
where πv denotes the seroconversio n rates for the vth vaccine (aQIV, aTIV -1, aTIV -2).
CBER Immunogenicity Criteria
The endpo ints of percent of subjects achieving seroconversio n and HI ti ter ≥ 1:40 at
Day 22 will be assessed against the criteria described in CBER Guidance Clinical Data
Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines ( FDA, 
2007):
The l ower bound of the two -sided exact 95% CIfor the percentage of subjects 
achieving seroconversion for HI antibody  shoul d meet or exceed 30% and
The l ower bound of the two -sided exact 95% CIfor the percentage of subjects 
achieving an HI ant ibody  titer ≥1:40 should meet or exceed 60%
Assuming that Y j
k~ B(1, π k), Zjk~ B(1, τ k), j=1,..,n, ident ical and independent Bernoulli 
distributed random variables with π krepresenting the unknown SC proporti on 
postvaccinat ionand τkrepresent ing the unknown SP (seroprotecti on, titer >1:40)
proporti on postvaccination in aQIV for strain k, where k denotes the 4 strains contained in 
aQIV vaccines, CBER requirements for the aQIV vaccine group translate into fo llowing 
hypothesis
H0k(SC): πk≤ 0.3 vs H1k(SC): πk> 0.3Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 81of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015H0k(SP): τk≤ 0.6 vs H1k(SP): τk> 0.6
All hypotheses related to CBER criteria will be tested on unadjusted 5% significance
level s.
8.4.2.2.2 Analysis Sets
The Per Protocol Set will be used for the primary  immunogenici ty analysis and a 
supporting analysis w ill be pe rformed using the Evaluable Set, a s noted in Section 8.3.4 . 
Evaluable Set –Immunogenicit y Analysis .Duplicate tables o f primary  and secondary 
immunogenicit y analyses m ay also be produced based on the Eval uable population if 
there is >1% difference in the total number of subjects between the Per -Protocol 
Popul ation and the Evaluable Population. 
8.4.2.
2.3 Statistical Methods
All statistical analyses for HI titers will be performed on the logarithmicall ytransformed 
(base 10 ) values. Individual HI titers below the detection limit (<10) will be set to half o f 
that limit (5) .
Co-primary immunogenicit y endpo ints of GMT and SCR for each virus strain contained 
in the vaccine will be assessed for subjects ≥ 65 y ears overall. For A/H1N1 and A/H3N2 
strains the two aTIV groups will be pooled. 
Primary analysis will be performed for subjects ≥ 65 years for the Per -Protocol Set. The 
difference in SCRs will be presented with e xact 95% (CIs). Each of the four strains will
be analyzed separately.
For immunogenicit y data, i t may be reasonable to consider missing immunogenicit
y
values as missing completely  at random  (MCAR), i.e. not informat ive. Therefore, the 
immunogenicit y analysis will  com prise a com plete case analysis onl y, wi thout 
introducing any bias. Imputation methods will not be used .
To determine the GMT ratio (adjusted analysis) a general linear model (GLM) will be 
fitted on l og transform ed (base ten ) post -vaccinat ion HI titer as the outcome variable and 
terms for covariates: vaccine treatment, pre -vaccination HI titer, age stratum, gender , 
vaccination history , age -by-vaccine interaction and study  site.Potenti al covariate 
interact ion effects will also be examined in the fit of the GLM .From  the m odel,an 
adjusted di fference in least square means (on the log scale) will be produced with 95% 
confidence limit s. The estimated difference and the confidence limits will be back 
transformed to obtain an adjusted GMT ratio with 95% confidence limit s. Each of the 
four strains will be analyzed separately . The adjusted GMT ratio will be the result for 
which the non -inferiorit y assessment of the HI GMT co -primary endpo int will be based 
on. Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 82of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015The stati stical models might be reduced in case they  fail to converge. Further details will
be provided in the Statist ical Analysis Plan.
The complete set of covariates that may be used in the model to calculate the adjusted 
GMT ratio will include treatment group (3 treatments), age sub- group ( 3categories, (≥65-
74, ≥75-84, and ≥85y ears), sex (m ale or female), influenza vaccinat ion received prior 
year (Y or N), prevaccinat ionmean GMT ti ter (value) and investigator site (site 
ident ifier)
The GLM specificat ion is:Adjusted Analysis GMT Model: Log- transformed P ost-
vaccination HI Titer = Vaccine + Age Strata + Gender + Vaccinat ion History  [y/n] + Log -
transformed Prevaccinat ion HI Ti ter + Si te + Age Strata*Vaccine.
For any strain, the interact ion term Age Strata*Vaccine will be removed from the fit of 
the model ifit is assessed to be not significant.
The m easure of the unadjusted GMT ratio based on post- vaccinat ion GMTs only will also 
be presented.
In line with the FDA Guidance on seasonal inactivated influenza vaccines (Guidance for 
Industry Clinical Data Needed to Support Licensure of Seasonal Inactivated Influenza 
Vaccines 2007) .  aQIV will be considered to be noninferior to aTIV if, for each of the 
four strains, the following statistical criteria are met: 
The upper bound of the two -sided95% Confidence Interva l (CI) for the rati o of 
the GMTs does not exceed 1.5. The GMT ratio will be calculated by  GMT aTIV/
GMT aQIV
The upper bound of the two -sided 95% CI for the difference between the SCRs 
does not exceed 10%. The difference in SCR will be calculated by πaTIV– π aQIV
To achieve the CBER criteria: 
The l ower bound of the two- sided 95% confidence interval for the percentage of 
subjects achieving seroconversio n for HI ant ibody  shoul d meet or exceed 30%
The l ower bound of the two- sided 95% confidence interval for the percentage of 
subjects achieving an HI antibody  titer≥ 40 should meet or exceed 60%
Binary data ( ie, percentages of subjects with seroconversio n and with titer ≥ 1:40) will be 
summarized for each group using unadjusted estimates and will be repor ted together with 
two-sided exact 95% C Is. No mult iplicity adjust ment to the CI levels will be 
implemented.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 83of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Handling of missing values for Immunogenicity Data:
For immunogenicit y data, i t may be reasonable to consider missing immunogenicity
values as mi ssing com pletely  at random  (MCAR), ie, not informative. Therefore, the key
secondary  analysis will comprise a com plete case analysis only, without introducing any
bias. Im putati on m ethods will not be used. Further details of the statist ical methods will 
beprovi ded in the SAP.
8.4.3 Analysis of Secondary Objective(s)
8.4.3.1 Analysis of Secondary Safety Objective(s)
Not applicable.
8.4.3.2 Analysis of Secondary Efficacy Objective(s)
Not applicable.
8.4.3.3 Analysis of Secondary Immunogenicity Objective( s)
Characterization of immunogenicity of aQIV, aTIV -1 and aTIV -2:
Themeasures of immunogenicit y of aQIV, aTIV -1 and aTIV -2 will be assessed in terms 
of HI antibodi es. Serum  HI ant ibody  titers against the 4 influenza vaccine strains will be 
used to calcula te: 
GMT: Geom etric mean of HI ti ters on Day 1 and Day 22
GMR: The geo metric mean of the fol d increase of post -vaccinat ion HI ti ter over 
the pre -vaccination HI titer (Day 22/Day 1 )
The percentage of subjects with a titer ≥ 1:40 at Day 1 and Day 22
SCR: the percentage of subjects with either a prevaccination HI titer < 1:10 and a 
postvaccinat ion HI titer ≥ 1:40 or a prevaccinat ion titer ≥ 1:10 and a ≥ 4 -fold 
increase in postvaccination t iteronDay 22
Superiority of immunologic response for aQIV vs aTIV:
Superi ority of aQIV over aTIV -1 and aTIV -2 for ant ibody  response to the alternate B 
strain will be assessed using the GMT ratio ( GMT aTIV/GMT aQIV) and difference in SCR Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 84of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015(SCR aTIV–SCR aQIV) at Day  22. Point estimates and 95% confidence limits will be 
obtaine d as described for the primary  endpoint. Superiorit y will be declared if the upper 
limit of the two -sided 95% CI for the difference i n SCR aTIV–SCR aQIV) is < 0 and the 
upper limit of the two- sided 95% CI for the GMT ratio ( GMT aTIV/GMT aQIV) is < 1 for 
both B strains.
8.4.3.3.1 Statistical Hypotheses
No stati stical testing will be performed for the first secondary  immunogenicit y
objectives.
Superiority of B -strain response (geometric mean titers and proportions of subjects w ith 
seroconversion) :
For superio rity of aQIV B strain response, the hypotheses are that immuno logically aQIV 
is superior compared to aTIV -1 and aTIV -2 for the B strain that is not included in each 
TIV vaccine separately . In mathemat ical form, these are:
H0k(GMT): GM Trk ≥1  vs H 1k(GMT) GMTrk <1  for k=1,2
and
H0k(SCR): Dk ≥0  vs H 1k(SCR) Dk <0  for k=1,2
where GMTrkis the ratio of geom etric mean ti ter GMT aTIV-k/GMT aQIV of mismatched B 
strain for k=1, 2, and Dkis the differences πaTIV-k–π\aQIV of mismatched B strai n Day 22 
SCR differences for k=1,2.
8.4.3.3.2 Analysis Sets
The secondary  objective superi ority testingwill beperform ed using the Per Protocol Set 
(PPS).
8.4.3.3.3 Statistical Methods
All statistical analyses for HI titers will be performed on the l ogarithmically transform ed 
(base 10 ) values. Individual HI titers below detection limit (<10) will be set to half o f that 
limit (5).
Unadjusted for GMTs, GMRs and pertaining two-sided 95% CIs will be calculated 
assuming log- normal distribut ion of the titers and will be co mpleted by  providing 
minimum, maximum and median t iters for each vaccine group. Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 85of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Binary data (ie, percentages of subjects with seroconversio n and with titer ≥ 1:40) will be 
summarized for each group using crude est imates and will be reported together with 2 -
sided exact 95% CIs. No mult iplicity adjust ment to the CI levels will be implemented. 
For immunogenicit y data, i t may be reasonable to consider missing immunogenicit y 
values as missing completely  at random  (MCAR), ie, not informative. Ther efore, the key  
secondary  analysis will comprise a com plete case analysis only, without introducing any  
bias. Im putati on m ethods will not be used.
Further details of the statist ical metho ds will be provided in the SAP.
8.4.4 Secondary Safety Objective
8.4.4.1 Analysis of Extent of Exposure
The number and percentage of subjects actually receiving the vaccinat ion will be 
summarized by  vaccine group.
8.4.4.2 Analysis of Solicited Local, Systemic and Other Adverse Events
Solicited local AEs include: inject ion site ery thema, indurat ion, ecchymo sis and pain.
Solicited systemic AEs include: loss of appetite, nausea, fat igue, generalized myalgia,
generalized arthralgia, headache, chills, vomit ing, di arrhea.
All solicited adverse events will be summarized according to defined severit y grading 
scales.
Frequencies and percentages of subjects experiencing each adverse event will be 
presented for each symptom severit y. Summary tables showing the occurrence of any  
local or systemic adverse event overall and at each time p oint will also be presented.
Postvaccinat ion solicited adverse events reported from Day 1 to Day  7 will  be 
summarized for the intervals Day 1 -3, Day  4-7, Day 1 -7 by maximal severit y and by  
vaccine group, excluding the 30- minute measurement, which will be s ummarized 
separately . Injecti on-site ery thema, ecchymo sis and indurat ion will be summarized 
according to categories based on linear measurements. Please refer to the SAP for 
definit ions of categori es. 
Inject ion site pain and systemic adverse events (exce pt fever) occurring up to 7 days after 
each vaccination will be summarized according to “mild”, “moderate” or “severe” 
categori es. For the definit ion of severit y grades please refer to Section 7.1.1 , Solicited 
Adverse Events of the protocol.
Each so licited local and systemic adverse event will also be further summarized as “none” 
versus “any”. “Any” will include measurements with a diameter of at least 1 mm.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 86of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Implausible measurements (for further definit ion see S AP) will be left out of the analysis.
Use of antipyret ics and analgesics will be summarized by  frequency and percentage of 
subjects reporting use. Summaries by t ype of use (prophylact ic versus treatment) and by 
vaccine group will be provided. The influence of antipyretics and analgesics use on the 
occurrence of specific adverse events (e.g., fever, pain) may be assessed.
Body  temperature will be summarized by  0.5 °C and 1.0 °C increments from 36.0 °C up 
to ≥40 °C and will be broken down according by route o f measurement. In addit ion, fever 
will be summarized according to “mild”, “moderate” or “severe” categorizat ion. For the 
definit ion of severit y grades please refer to the SAP.
8.4.4.3 Analysis of Unsolicited Adverse Events
This analysis applies to all adv erse events occurring during the study , judged ei ther as 
probably  related, possibly  related, or not rel ated to vaccination by  the Invest igator, 
recorded in AE CRF, with a start date on or after the date of first vaccinat ion. AE starting 
prior to the first vaccinat ion will only  be listed. The ori ginal verbatim terms used by  
investigators to ident ify adverse events in the CRFs will be mapped to preferred terms 
using the MedDRA dict ionary. The adverse events will then be grouped by  MedDRA 
preferred terms into frequency tables according to system organ class.
All reported adverse events, as well as adverse events judged by the invest igator as at 
least possibly  related to study  vaccine, will be summarized according to sy stem  organ 
class and preferred term within system  organ cl ass (SOC). These summaries will be 
presented by vaccinat ion group and by interval o f study  observat ion. When an adverse 
event occurs more than once for a subject, the maximal severit y and strongest rel ationship 
to the vaccine group will be c ounted.
Separate summaries will be produced for the fo llowing categori es:
Serious adverse events
Adverse events that are possibly or probably related to vaccine
Adverse events of special interest
New onset of chronic disease
Adverse events leading to withd rawa l
Adverse events result ing in death
Data list ings of all adverse events will be provided by subject. In addit ion, adverse events 
in the categories above will be provided as listed data.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 87of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Forhandling of missing data ,the entire study  period will be divi ded into disj oint intervals 
based upon the time and event schedule in the protocol:
Solicited AEs: 30 min, 6h- Day 3, Day  4-Day 7, and one overall interval: 6h -Day 7.
Unsolicited AEs: [Day  1-22], [Day  23-181], and [Day  1-181].
No im putati on of  missing so licited or unsolicited AEs will be used. The percentage of 
subjects wi th missing so licited AE assessments (eg, missing Diary Card) and missing 
Safety Phone Call or safet y assessment will be reported for each time period.
8.4.4.4 Analysis of Safety Laboratory Values
Not applicable.
8.4.5 Analysis of Exploratory Objectives
The exploratory  objectives are:
1.Addit ional optional object ives include characterization of the immunogenicit y of 
aQIV using other immuno logical assays (e.g., virus neutralizat ion [MN] or anti -
neuraminidase ant ibody  assays may  be perform ed)
2.To expl ore the associ ation between immune response after administration of aQIV 
or the aTIV -1, containing the same virus strains as the US -licensed adjuvanted 
trivalent influenza vaccine, or the aTIV -2 contai ning the alternate B strain by 
baseline characterist ics.
Exploratory immunogenicity objective 1
Exploratory  objectives rel ated to the MN -assay, immune response to heterologous 
influenza strains, or different ant igens will be evaluated using similar method s for l og
norm al. binomial data, and GMT and SCR as described in the statist ical method for 
primary  and secondary immunogenicit y analysis.
Exploratory immunogenicity objective 2
GMTs: Geometric mean of HI titers prevaccinatio n (Day 1) and at Study Exit 
Visit
Percentage of subjects with four -fold rise
Analyses of the exploratory  immunogenicit y endpoints will be performed with adjust ment 
for covari ates including prevaccinat ion titer, vaccinat ion history , age and gender to 
evaluate the contribut ion of these fa ctors to variations in the immune response. The 
covari ate adj ustment will be performed with all o f the specified covariates in the general 
linear model.
The full model s pecificat ion for the GMT titers will be:Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 88of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Log-transformed Post-Vaccination HI Titer = Vaccine + Age Strata + Gender+ 
Vaccination History + Log- trans formed Pre vaccination HI Titer . 
The full model specificat ion for the SCR rates will be:
SCR = Vaccine + Age Strata + Gender + Vaccination History + Log-transformed Pre-
vaccination HI titer 
Seroc onversio n rates will be analyzed using a logistic regressio n model, and GMT ti ters 
will be log transformed (base 10 ) and analyzed with a general  linear m odel. Pre-
vaccination t iters will be log transformed and entered as a continuous covariate. 
Vaccinat ionhistory  will be a categorical variable indicat ing whether or not an individual 
received an influenza vaccination in the previous year. If the proportion vaccinated in the 
previous year is close to 100% then this covariate may be omitted to avoid creating an 
unstable model. Age will be entered according to the predefined strata (≥65-74, ≥75-84, 
and ≥85years) . For the logist ic regressio ns,the odds rati os will be presented with 95% 
CIs for each effect in the model. For the GLM least square mean est imates for the GMT 
ratio will  be presented wi th 95% confidence limits for each effect in the model. 
Further d etails of the analysis o f exploratory  be provi ded in the SAP.
8.5 Sample Size and Power Considerations
aQIV will be tested against aTIV com parators. The tr eatment randomizat ion rati o is 2:1:1 
(aQIV: aTIV -1: aTIV -2). This study is powered to achieve 80% power to demonstrate 
noninferiorit y over 8 co -primary endpo ints, seroconversio n rates for 4 strains, GMT for 4 
strains using a one -sided alpha of 0.025 for ea ch comparison. No adjust ment for multiple 
endpo ints will be made.
For com parisons of SCR a noninferiorit y margin of 10% (aTIV –aQIV) will be 
employed.It is assumed that the SCRs for A/ H1N1, A/ H3N2 and B strains for TIV are 
73%, 73% and 40% respectively . These estimates are based onthe estimated SCR rates of 
histori cal data, nam ely study  protocol  V70_27 . It has been assumed that there is no 
difference in terms of SCR between aQIV and aTIV for all strains. For comparison of the 
GMT ratio, a noninferiorit y of 1.5 (aTIV/aQIV) will be emplo yed. It is assumed that there 
is no difference between aQIV and aTIV ( i.e.,a ratio of 1) and that the standard deviat ion 
of log (ti ter) i s 1.2.
Under these assumptions ,N evaluable = 800 in the aQIV group and 400 in each aTIV 
group provi ding 800 and 800 subjects receiving aQIV and aTIV respectively  for 
comparisons of A strains, and 800 and 400 subjects receiving aQIV and aTIV 
respectively  for com parisons o f B strains. This provides a total N evaluable = 1600. These 
numbers provi de 99.45% power to detect differences in SCR for each A strain and 91.29 
% power for each B strain, providing overall 82.42% power for the 4 SCR tests.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 89of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015For GMT ratio tests each A strain test will have 100% power and each B strain test will 
have 99.98% power, providing 99.96% power for the 4 GMT ratio tests and consequent ly 
82.39% power for the 8 co -primary endpo ints.  Overall 1600 evaluable subjects will be 
requi red. Allo wing for a 10% drop- out N=1778 subjects will be recruited (Sample size 
calculat ions were performed using PASS v12).
The immunogenicit y was powered to m eet the cri teria prespecified in the CBER guidance 
for acceptable immunogenicit y: namely, 
the lower bound of the two -sided 95% confidence interval for the percent of 
subjects achieving seroconversio n shoul d exceed 30%, and 
the lower bound of the two -sided 95% confidence interval for the percent of 
subject achieving HI ant ibody titer ≥ 40 should exceed 60%
With a sa mple size of N =800 (evaluable) subjects for the aQIV group if the population 
SCR for A/ H1N1, A/ H3N2 and B strains for TIV is 73%, 73% and 40% respectively 
then the probabilit y of observing a seroconversio n rate tha t is significant ly greater than 
30% i s approximately  100% (f or the A/H1N1), 100%for A/H3N2 and 100% (for the B -
strains).
With a sample size of N=800 (evaluable) subjects for the aQIV group if the population SP 
rates for A/ H1N1, A/ H3N2 and B strains for T IV is 91%, 99% and 64.6% respectively 
(as observed in V70_27) then the probabilit y of observing a SP rate that is significant ly 
greater than 60% is approx imately  100% (for the A/H1N1), 100% for A/H3N2 and 
76.47% (for the B -strains).
Table 8. 5-1summari zes the list of all co-primary endpo ints with strains, the planned
noninferiorit y margin and underlying assumpt ions used for the sample size co mputations.
Table 8. 5-1: Summary of Assumptions Used for Sample Size Calculations
NI co mparison H1N1
H3N2 B strains
Test si gnificance level, alpha (1 -sided) 2.50% 2.50% 2.50%
Noninferiorit y Margin for the SCR 
comparison (%)10 10 10
Assumed true SCR 73% 73% 40%
Power for SCR comparison tests for 99.45% 99.45 % 91.29%Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 90of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015each strain (%)
Glob al Power for 4 SCR Endpoints 82.42%
Noninferiorit y Margin for the GMT 
ratio1.5 1.5 1.5
Commo n Standard Deviat ion of 
loge(titer) 1.2 1.2 1.2
Power for GMT ratio tests for each 
strain (%)99.99% 99.99% 99.98%
Global Power for 4 GMT ratio 
Endpoints99.96%
Global Power for 8 Co -primary 
Endpoints82.39 %
CBER Cri teria H1N1 H3N2 B strains
Test si gnificance level, alpha (1 -sided) 2.50% 2.50% 2.50%
Seroconvers ion Thresho ld 30% 30% 30%
Assumed true SCR 73% 73% 40%
Power for SCR 100% 100% 100%
Global P ower for 4 SCR Endpoints 100%
Thresho ldfor Rate >1:40 60% 60% 60%
Assumed T rueRate >1:40 91% 99% 64.6%
Power for R ate >1:40 100% 100% 76.47%
Global Power for 4 >1:40 Endpoints 76.47%
Global Power for the Second 8 Co - 76.47%Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 91of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015primary Endpoints (CBER Cri teria)
A safet y database of N = 800 has a 95% chance of detecting AEs that occur at a rate of 1 
in 267. With a single stratum o f 800 participants, the probabilit y of observing at least one 
event for events with populat ion rates of 1 in 300, 1 in 200, and 1 in 100 are 93.1%, 
98.2% and 100%, respectively. 
8.6 Interim Analysis
No interim analysis is planned for this study .
.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 92of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20159. SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING
In order to ensure consistency  across si tes, study  monitoring and audit ing will be 
standardized and performed in accordance with the Sponsor’s or delegated contract 
research organizat ion’s (CRO) standard operating procedures and applic able regul atory  
requi rements (eg , FDA, EMA, and ICH guidelines).
Prior to enrol lment of the first st udy subject, Seqirus or del egate will  train invest igators 
and/or their study  staff on the study  protocol , all applicable study  procedures, 
docum entati on practices and all electronic systems. CRFs supplied by the Sponsor must 
be co mpleted for each e nrolled subject (see Section 8.3.1, All Enro lled Set for definit ion 
of enro lled subject). Documentation of screened but not enrolled subjects must be 
maintained at the site and made available for review by  the si te monitor. Data and 
docum ents will  be checked by the Sponsor and/or monitor.
9.1 Source Documentation
Prior to the start of the study , the si te staff participating in the study  conduct will be 
instructed on what documents will be required for review as source docum ents. The kinds 
of docum ents that will serve as source documents will be agreed b etween Sponsor or 
delegate and I nvest igator and designees and specified in the SDA prior to subject 
enrol
lment.
In addit ion, source documentation must include all of the following: subject ident ificat ion 
(on each page), eligibilit y and partici pation, proper informed consent procedures, dates of 
visits, adherence to protocol procedures, adequate reporting and fo llow-up of  adverse 
events, documentation of prior/concomitant medication/vaccines, study  vaccine 
recei pt/dispensing/return records, study  vaccine administrati on inform ation, any data 
collected by  a tel ephone conversation wit h the subject and date of complet ion and reason.
Thesubject must also allow access to the su bject’s medical records. Each sub ject must be 
inform ed of this pri or to the start of the study  and consent for access to medical records 
that may be required in accordance with local regulat ions.
All safet y data reported by  subjects m ust be wri tten down in source docum ents pri or to 
entry  of the data into CRFs. If there are mul tiple sources of informat ion (e.g., Diary Card , 
verbal report of the subject, telephone contact details, medical chart) supporting the 
diagnosis of an adverse event, these sources must be ident ified in the source documents, 
discrepancies between sources clarified, the ult imate diagnosis must be justified and 
written in the source documents, and this diagnosis must be captured in the Adverse 
Event CRF (AE CRF). The AE CRF must also captu re which source(s) of informat ion 
were used to determine the adverse event (e .g.subjec t recall, medical chart, Diary Card ).Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 93of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 20159.2 Study Monitoring, Auditing and Source Data Verification
Prior to enrol lment of t he first study subject, Seqirus or its designee (eg, a CRO) will 
develop a Clinical Monitoring Plan to specify  how centralized and/or on -site monitoring, 
including clinical specimens reconciliat ion, will be performed for the study . Study  
progr ess will be mo nitored by  Seqi rus or its desi gnee as frequent ly as necessary  to ensure:
that the ri ghts and well -being of human subjects are protected
the reported study  data are accurate, complete, and verifiable from the source 
docum ents and
the conduct of the study  is in co mpliance wi th the current approved 
proto col/amendment(s), GCP and applicable regulatory  requi rements
Contact details for the Seqirus team  or its desi gnee invo lved in study  monitoring will  be 
provi ded to the I nvest igator. Study  data recorded on CRFs will be verified by  checking 
the CRF entries ag ainst source documents in order to ensure data completeness and 
accurac y as requi red by the study  protocol . 
Data verification may  also be performed through a centralized review of data (eg , 
checking for outliers or other ano malies). Ad ditional docum ents such as the I nvest igator 
Site File, pharmacy records, and informed consent documentation must also be available 
for review if requested. Arrangements for monitoring visits will be made in advance in 
accordance with the monitoring plan, except in case of em ergency.
The I nvestigator and/or site staff must make source documents of subjects enrolled in this 
study  available for inspect ion by Seqiru s or i ts representative at the time o f each 
monitoring visit and Sponsor audits, when applicable. These documents mu st also be 
available for inspect ion, verificat ion and copying, as required by regulations, by o fficials 
of the r egulatory  health authori ties (e.g. FDA, EMA an d others) and/or ECs/IRBs. The 
Invest igator and study site staff must comply wit h applicable priva cy, data protecti on and 
medical confidentialit y laws for use and disclosure of informat ion related to the study  and 
enrolled subjects.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 94of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 201510. DATA MANAGEMENT
10.1 Data Entry and Management
In thi s study , all clinical data (including, but not limited to, AE/S AEs, concomitant 
medicat ions, medical history , and physical  assessments), safety  data, and immunogenicit y 
data will be entered onto case report forms (CR Fs) in a timely fashio n by the I nvest igator 
and/or the Invest igator’s dedicated site staff. Data entere d onto CRFs are stored on a 
secure website. The data collected on this secure website are assimilated into an 
electroni c data capture (EDC) system, which is compliant with Tit le 21 Part 11 policies of 
the Code of Federal Regulat ions (FDA ,
1997). The data sy stem  includes password 
protecti on and internal qualit y checks. The EDC system will be designed and validated by  
the Sponsor prior to activat ion for data entry  by sit es. The I nvest igator or designated 
delegate m ust rev iew data entered and electronically sign the CRFs to verify their 
accuracy .
Access to the EDC sy stem  for data entry  or review will require training and dist inct 
individual access code assignments to th ose si te staff members who will be entering study  
data and those invo lved in study  oversi ght who m ay review study  data. Data are collected 
within the EDC system, to which the Sponsor and site monitors have exclusively  “read 
only” access.
10.2 Data Clarification
As part of the conduct of the trial, the Sponsor may have quest ions about the data entered 
by the site, referred to as queries. The monitors and the Sponsor are the only part ies that 
can generate a query . All correcti ons and clarificatio ns will be entered into the EDC 
system  and will  be identified by th e person entering the informat ion, the reason for the 
change, as well as the time of the changes made. If changes are made to a previously and 
electroni cally signed CRF, the invest igator must confirm and endorse the changes.
10.3 Data Protection
Seqirus respects the subjects’ rights to privacy and will ensure the confident iality of their 
medical informat ion in accordance wit h all applicable laws and regulat ions.
The Sponsor as Data Controller according to the European Directive on the protection of 
individ uals wi th regard to the processing of personal data and on the free movement of 
such data ( European Parliament, 1995 ) confirms herewith compliance to Directive 
95/46/EC in all stages of Da ta Management.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 95of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 201511. RECORD RETENTION
Invest igators must retain all s tudy records required by  Seqiru s and by the applicable 
regul ations in asecure and safe facilit y. The I nvestigator m ust consul t a Seqi rus
representative before disposal o f any study  record s, and must notify the Sponsor of any 
change in the location, disposit ion, or custody  of the study  files. Essent ial docum ents 
must be retained for 15 y ears. “Essent ial docum ents” are defined as documents that 
individually  and collect ively permit evaluat ionof the conduct of a study  and the qualit y 
of the data produced. These documents should be retained for a longer period, however, if 
requi red by the applicable nat ional regulatory  or insti tutional requirements. 
Laboratory  samples will be retained for a pe riod of up to 15 y ears.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 96of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 201512. USE OF INFORMATION AND PUBLICATION
Seqirusassures that the key  design el ements of this protocol will be posted in a publicly  
accessible database such as clinicaltrials.gov, and in co mpliance with current regulat ions.
Seqirusalso assures that key  resul ts of this clinical study  will be posted in a publicly 
accessible database wit hin the required time -frame fro m the end of study  as defined in 
Section 3.9, End of Study .
In accordance with standard ed itorial, ethi cal practices and current guidelines of Good 
Publicat ion Practice ( Graf,
2009), Seqirus will generally support publicat ion of 
multicenter studies only in their entiret y and not as individua l center data. In this case, a
Coordinat ing Investigator will be designated by mutual agreement prior to the start of the 
study . The Coordi nating I nvest igator will also sign the clinical study report on behalf o f 
the Principal I nvest igators ( CPMP, 2001 )
. Autho rship will be determined by mutual 
agreem ent and in line with Internat ional Commit tee of  Medical Journal Editors authorship 
requi rements. Any form al publicat ion of the study  in which contribution o f Seqirus
personnel exceeded that of convent ional monitorin g will be considered as a jo int 
publicat ion by the invest igator and the appropriate Seqiruspersonnel.
Seqirusmust be notified o f any intent to publish data collected fro m the study  and pri or 
approval  from Seqirusmust be obtained prior to submissio n for publicat ion.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 97of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 201513. ETHICAL CONSIDERATIONS
13.1 Regulatory and Ethical Compliance
The study  will be conducted in com pliance wi th the protocol, GCP and applicable 
regul atory  requi rement(s).
This clinical study  was designed and shall be implemented and reporte d in accordance 
with the ICH Harmonized Tripart ite Guidelines for Good Clinical Practice, wi th 
applicable local regulat ions: including European Direct ive 2001/20/EC, US Code of 
Federal Regulat ions Ti tle 21, and Japanese Ministry  of Heal th, Labor, and Welfa re. 
Seqiruscodes on protection of human rights, and with the ethical principles laid down in 
the Decl aration of Helsinki ( European Council 2001, US Code of Federal Regulat ions, 
ICH
, 1997).
13.2 Informed Consent Procedures
Eligible subjects m ay only  be included in the study after providing written informed 
consent ,as described in Section 5.1.1, Informed Consent . Befo re the start of the study , the 
Invest igator will have the informed co nsent and any  other m aterials that will be provided 
to the subjects reviewed and approved by the IRB/EC. This review and approval will be 
docum ented and stored w ith other study  docum ents. The I nvest igator or designee must 
fully infor m the subject or legal representative of all pertinent aspects of the study . A 
copy  of the wri tten informed consent will be given to the subject or the designee. The 
subject/designee must be allowed ample time to ask about the details of the study  and to 
make a decisio n as to wh ether or not to participate in the study . The subject (and/or legal 
representative (s) must sign the consent form indicating their agreement to participate in 
the study  before any  study -related procedures are conducted. The informed consent 
process may  be conducted up to 10 days prior to vaccination on D ay 1. If  the subject 
and/or legal representative (s) is unable to read and write, a witness must be present during 
the informed consent discussio n and at the time of informed consent signature.
Prior to the st art of the study, Seqiruswill provi de to invest igators a proposed informed 
consent form that complies with the ICH GCP guideline and regulatory  requi rements and 
is considered appropriate for this study . Any  changes to the proposed consent form 
suggested b
y the invest igator must be agreed to by  Seqirusbefore submissi on to the 
IRB/EC and a copy  of the approved versio n must be provided to the Seqirusmonitor after 
IRB/EC approval.
13.3 Responsibilities of the Investigator and IRB/EC
The protocol and the pro posed informed consent form must be reviewed and approved by 
a properly const ituted IRB/EC before study  start. Properly const ituted IRB/EC is defined Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 98of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015in ICH Guideline for Good Clinical Practice E6 (R1), Section 3 ( ICH, 1997) , and 
Integrated Addendum to ICH E6( R
2): Guideline for Good Clinical Practice ( ICH , 2016) . 
A signed and dated statement that the protocol and informed consent have been approved 
by the IRB/EC must be given to Seqirus before study  initiation. Prior to study  start and at 
any time the protocol is ame nded during study  conduct, the I nvest igator is required to 
sign a protocol  signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all o f the instructi ons and procedures found in this 
protocol  and to give access to all relevant data and records to Seqirus monitors, audi tors, 
SeqirusClinical Qualit y Assurance representatives, designated agents of Seqirus, 
IRBs/ECs, and regulatory  authori ties as requi red. If an inspection of the clinical site is 
requested by  a regul atory  authori ty, the invest igator must inform Seqirusimmediately  that 
this request has been made.
The I nvestigator also responsible for the fo llowing:
Maintaining a list of appropria tely qualified persons to whom the I nvestigator has 
delegated s ignificant study -related duti es
Dem onstrating the capabilit y of recruit ing the required number of suitable subjects 
within the recruit ment period.
Dem onstrating sufficient time and staffing to properly conduct and complete the study 
within the agreed study  period.
Ensuring that all persons assist ing wit h the study  are adequately  informed about the 
protocol , the investigational product(s), and their study -related duti es and funct ions
Ensuring tha t appropri ately  trained heal th care professio nals are responsible for all 
study -related medical decisio ns and for ensuring appropriate medical care of subjects 
experiencing any  adverse event related to the study
If permissio n todo so is given by the subje ct(or legal representative ), ensuring that 
the subject’s primary healt hcare provider is informed of the subje ct’s parti cipat ion in 
the study
The I nvestigator should not implement any deviat ion fro m, or changes of the protocol 
without agreement by  the Spon sor and prior review and documented approval/ favorable
opinio n from the IRB/IEC of an amendment, except where necessary to eliminate an 
immediate hazard(s) to study  subjects, or when the change(s) invo lves only logist ical or 
adminis trative aspects of the s tudy (e.g. change in mo nitor(s), change of telephon e 
number(s)). In addit ion, the I nvest igato r, or person designated by the I nvest igator, should 
docum ent and explain any deviat ion from the approved protocol.
The I nvestigator may  implement a devi ation from,or a change o f, the protocol to 
eliminate an immediate hazard(s) to study  subjects with out pri or IRB/IEC 
approval /favo rable opinio n. As soon as possible, the implemented deviat ion or change, Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 99of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015the reasons for it, and, if appropriate, the proposed protocol a mendment(s) should be 
submitted:
(a) to the IRB/I EC for review and approval/favo rable opinio n
(b) to the Sponsor for agreement and, if required
(c) to the regulatory  authori ty(ies)
13.4 Protocol Amendments
An amendment is a written descript ion of change(s ) to or formal clarificat ion of a study  
protocol  which may  impact on the conduct of the clinical study , potenti al benefi t of the 
clinical study , or m ay affect subj ect safet y, including changes of study  object ives, study  
design, subject population, sample s izes, study  procedures, or significant administrative 
aspects. An administrative change of a study  protocol  is a minor correction or 
clarificati on that has no si gnificant impact on the way  the clinical  study  is to be conducted 
and no effect on subject saf ety (e.g. change of telephone number(s), logist ical changes). 
Protocol  amendments m ust be approved by  Seqirus , heal th authori ties where required, 
and the IRB/EC. In cases when the amendment is required in order to protect the subject 
safet y, the am endment c an be implemented prior to IRB/EC approval. Notwithstanding, 
the need for formal approva l of a protocol  amendment, the I nvest igator is expected to take 
any immediate action required for the safet y of any subject included in this study , even if 
this action represents a deviat ion from the protocol. In such cases, Seqirusshoul d be 
notified o f this action, the IRB/EC at the study  site, and, if required by local regulat ions, 
the relevant heal th authori ty) shoul d be informed wi thin 10 working days.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 100of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 201514. REFEREN CE LIST
Hak EF. Development and validat ion of a clinical predict ion rule for hospi talizat ion due 
to pneumonia or influenza or death during influenza epidemics amo ng communit y
-
dwelling elderly persons. J Infect Dis 2004;189(3):450 -458.
Food & Drug Administr ation (FDA). Guidance for Industry : Clinical  Data Needed to 
Support the Licensure of Seasonal Inact ivated Influenza Vaccines. U S Food and Drug 
Administrati on Hom e Page , Center for Bi ologics Evaluat ion and Research, May 2007.
Temte JL, Prunuske JP. Seasona l influenza in primary care settings: review for primary 
care physicians. WMJ 2010 Aug;109(4):193-200.
Rothberg MB, Haessler SD, Brown RB. Complicatio ns of viral influenza. Am J Med 
2008 Apr;121(4):258 -64.
Fiore AE, Shay  DK, Broder K et al . Prevent ion and control of seasonal influenza with 
vaccines: recommendations of the Advisory  Commi ttee on Immunizati on Practices 
(ACIP), 2009. MMWR Reco mm Rep 2009 Jul 31;58(RR -8):1-52.
Monto AS. Epidemio logy of influenza. Vaccine 2008 Sep 12; 26 Suppl 4:D45 -8.
Osterholm, MT, Kelley NS et al. Efficacy and effectiveness of influenza vaccines: a 
system atic review and meta -analysis. Lancet Infect Dis 2012;12(1): 36 -44.
Beyer WE, McElhaney J, et al. Cochrane re -arranged: support for policies to vaccinate 
elderly  people against influenza. Vaccine 2013;31(50): 6030- 6033.
Goodwin K, Viboud C et al. Ant ibody  response to influenza vaccinat ion in the elderly: a 
quant itative review. Vaccine 2006;24(8):1159- 1169.
Sasaki S, Sullivan M ,et.al. Limi ted efficacy of inactivated influenza vaccine in elderly  
individual is associated with decreased production of vaccine -specific antibodies. J Clin 
Invest 2011;121(8): 3109- 3119.
Frey SE et al . Com parison of the safet y and immunogenicit y of anMF59 -adjuvanted wi th 
a non -adjuvanted seasonal  influe nza vaccine in elderly subjects. Vaccine 2014;32:5027 -
5034.
Rota PA, Wallis TR, Harmon MW et al. Cocirculation of two dist inct evo lutionary 
lineages of influenza t ype B virus since 1983. Virology 1990;175(1):59 -68.Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 101of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin 
Immunother 2012; 8(1):81- 8.
Lo YC, Chuang JH et al. Surveillance and vaccine effect iveness of an influenza epidemic 
predominated by  vaccine -mismatched influenza B/Yamagata -lineage viruses in Taiwan, 
2011- 12 season . PLoS One 2013;8(3): e58222.
Belshe, RB.  The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 
28 Suppl 4: D45-53.
World Heal th Organizat ion (WHO); Reco mmended composit ion of influenza virus 
vaccines for use in the 2017 -2018 norther n hemisphere influenza season. Accessed 11 
May 2017 at: 
http://www.who.int/influenza/vaccines/virus/recommendat ions/2017_18_north/en/
Centers for Disease Control and Prevent ion (CDC) (2014). Ant igenic Characterizat ion. 
Accessed 16 May  2017 at: www.cdc.gov/flu/professio nals/laboratory /antigenic.ht m 
Code of Federal Regulat ions (1997): Food and Drug Administration, U.S. Department of 
Health and Human Services: Tit le 21, Part 11: El ectroni c Records El ectroni c Signatures. 
Federal Register 62: 13464
European Parliament (1995): Direct ive 95/46/EC of the European Parliament and of the 
Council of 4 April 2001. Official Journal o f the European Communit ies. L 281/31 -39
Graf C , Batti sti WP, Bridges D. Good publicat ion practice for communicating co mpany 
sponsored medical research: the GPP2 guidelines. BMJ 2009;339: b4330
Committee for Proprietary  Medicinal  Products (CPMP) (2001): Note for Guidance on 
Coordinat ing Investigator Si gnature of Clinical Study  Reports. The European Agency for 
the Eval uation of Medicinal Products.
European Parliament (2001): Direct ive 2001/20/EC of the European Parliament and of 
the Council o f 4 April  2001. Official Journal of the European Communit ies. L 121/34 -44
ICH (1997) ICH Harmonised Tripartite ICH Guideline for Good Clinical Practices E6 
(R1). Federal Register, 62 (90): 25691 -25709
ICH (2016) ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline 
for Good Clinical Pract ice E6(R2). Ac cessed 12 May  2017 at: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6
_R2__Step_4.pdfDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 102of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015ICH (1998) ICH Harmonised Tripartite ICH Guideline for Statist ical Principles for 
Clinical Trials E9. Federal Register, 63 (179): 4958 3
U.S. Department of Health and Human Services, Food and Drug Administration, CBER 
(2009): Gui dance for Industry  Patient -Reported Outcome Measures: Use in Medical 
Product Development to Support Labeling Claims
59th World Medical Associat ion General Assembl y (October 2008) Decl aration of 
Helsinki -Ethical Principles for Medical Research Invo lving Human Subjects. Seoul, 
KoreaDoc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 103of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015APPENDIX 1: EXAMPLES OF PRE -EXISTING MEDICAL CONDITIONS FOR 
CALCULATION OF RISK SCORE
1. Pulmonary Disease
a. Asthma
b. Chronic br onchit is
c. Chronic obstructive lung disease or emphysema
d. Pneum oconi oses
e. Pulmo nary fibrosis
f. Pulm onary tubercul osis and diseases due to other mycobacteria
g. Sarcoi dosis
2. Heart Disease
h. Coronary  artery  disease
i. Valvular heart di sease
j. Congeni tal heart disease
k. Hy pertensive heart disease
l. Ischemic heart disease
m. Diseases of pulmo nary circulat ion
n. My ocardi tis
o. Arrhy thmias, including atri al fibrillat ion
p. Congest ive heart failure
3. Renal Disease
q. Hy pertensive renal disease
r. Dialysis
s. Renal transplantation
t. Nephri tis, nephroti c syndrom e, nephrosi s
u. Chroni c pyel onephri tis
v. Di alysis and transplant
4. Dementia or stroke
w. Neurol ogic and neurodevelopmental condit ions [including disorders of the 
brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy , epilepsy Doc ID: 83409929, Version: 1, Approval Date: 18May17
 Seqirus Inc. Confidential Protoc ol V118_20
18May 17 Version 1.0 Page 104of 104
PRO -01 TEMP 06 / Atla s No. 293620
Version No. 4/ Version Date: January 29, 2015(seizure disorders), stroke, intellectual disabilit y (mental  retardati on), m oderate to 
severe developmental delay, muscular dy strophy , or spinal  cord injury ].
x. Cerebrovascular disease
y. Dement ia
z. Hereditary  and degenerative diseases of CNS
5. Non-hematological and hematological cancer (excluding cancer of the skin 
other than melanoma)Doc ID: 83409929, Version: 1, Approval Date: 18May17
吀栀椀猀 猀椀最渀愀琀甀爀攀 挀攀爀琀椀昀椀挀愀琀攀 椀猀 漀渀氀礀 瘀愀氀椀搀 眀栀攀渀 愀挀挀漀洀瀀愀渀椀攀搀 戀礀 愀氀氀 琀栀攀 瀀愀最攀猀 漀昀 琀栀攀 搀漀挀甀洀攀渀琀⸀ ⼀
䐀椀攀猀攀爀 一愀挀栀眀攀椀猀 椀猀琀 渀甀爀 稀甀猀愀洀洀攀渀 洀椀琀 愀氀氀攀渀 匀攀椀琀攀渀 搀攀猀 䐀漀欀甀洀攀渀琀攀猀 最ﰀ氀琀椀最⸀ ⼀
䰀愀 瀀爀攀猀攀渀琀攀 挀攀爀琀椀昀椀挀愀稀椀漀渀攀  瘀愀氀 椀搀愀 猀漀氀愀洀攀渀琀攀 猀攀 愀挀挀漀洀瀀愀最渀愀琀愀 搀愀 琀甀琀琀攀 氀攀 瀀愀最椀渀攀 搀攀氀 搀漀挀甀洀攀渀琀漀 挀甀椀 猀椀 爀椀昀攀爀椀猀挀攀Novartis
     䐀漀挀甀洀攀渀琀
䄀瀀瀀爀漀瘀愀氀 䌀攀爀琀椀昀椀挀愀琀攀 ⼀
        䘀爀攀椀最愀戀攀渀愀挀栀眀攀椀猀 䐀漀欀甀洀攀渀琀 ⼀
     
䌀攀爀琀椀昀椀挀愀稀椀漀渀攀 瀀攀爀 氀’愀瀀瀀爀漀瘀愀稀椀漀渀攀 搀椀 甀渀 搀漀挀甀洀攀渀琀漀
吀栀攀 椀渀搀椀瘀椀搀甀愀氀猀 氀椀猀琀攀搀 栀愀瘀攀 愀瀀瀀爀漀瘀攀搀 琀栀椀猀 搀漀挀甀洀攀渀琀 昀漀爀 椀洀瀀氀攀洀攀渀琀愀琀椀漀渀 甀猀椀渀最 愀渀 攀氀攀挀琀爀漀渀 椀挀 猀椀最渀愀琀甀爀攀 椀渀 琀栀攀
䄀琀氀愀猀 䔀䐀䴀匀⸀ ⼀ 䐀椀攀 愀甀昀最攀昀ﰀ栀爀琀攀渀 倀攀爀猀漀渀攀渀 栀愀戀攀渀 搀甀爀挀栀 椀栀爀攀 攀氀攀欀琀爀漀渀椀猀挀栀攀 唀渀琀攀爀猀挀栀爀椀昀琀Ⰰ 搀椀攀猀攀猀 䐀漀欀甀洀攀渀琀
椀洀 䄀琀氀愀猀 䔀䐀䴀匀 最攀渀攀栀洀椀最琀⸀ ⼀ 䰀攀 瀀攀爀猀漀渀攀 猀漀琀琀漀 爀椀瀀漀爀琀愀琀攀 栀愀渀渀漀 愀瀀瀀爀漀瘀愀琀漀 焀甀攀猀琀漀 搀漀挀甀洀攀渀琀漀 瀀攀爀
挀漀渀猀攀渀琀椀爀渀攀 氀’甀琀椀氀椀稀稀漀 ⠀氀’愀瀀瀀爀漀瘀愀稀椀漀渀攀 愀瘀瘀椀攀 渀攀 洀攀搀椀愀渀琀攀 昀椀爀洀愀 攀氀攀琀琀爀漀渀椀挀愀 猀甀 猀椀猀琀攀洀愀 䄀琀氀愀猀 䔀䐀䴀匀⤀⸀
) 
Title:  Seqirus Clinical Medical Lead 
Date: Thursday, 18 May 2017, 20:18   GMT 
Meaning: As an approver, I agree with the content and format of this document. / Als Genehmiger bin ich mit dem Inhalt und der Form
des Dokumentes einverstanden. / In qualità di Approvatore, concordo con il contenuto ed il formato di questo documento 
================================================Doc ID: 83409929, Version: 1, Approval Date: 18May17
